Conjugate, and pharmaceutical composition and application thereof
By providing a conjugate with a specific structure, the problem of scarcity of drugs that inhibit YAP/TAZ-TEAD in the prior art is solved, and effective inhibition of YAP/TAZ abnormally expressed cells is achieved. , has potential cancer treatment effects.
Patent Information
- Application Number
- CN202410673733.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-31
- Filing Date
- 2024-05-28
- Publication Date
- 2024-12-03
AI Technical Summary
In the prior art, there are fewer types of drugs that inhibit the YAP/TAZ-TEAD signaling pathway, and it is difficult to effectively treat cancer caused by abnormal expression of YAP/TAZ.
A conjugate is provided with a structure of A-L-M, wherein A, L and M are composed of specific structures and have good antiproliferative activity against sensitive cell lines NCI-H2052, MSTO-1H and A172 cells.
This compound showed significant antiproliferative activity on the target cell line and had potential effects on the treatment of cancer caused by abnormal expression of YAP/TAZ.
Smart Images

Figure BDA0004863402740000021 
Figure BDA0004863402740000022 
Figure BDA0004863402740000031
Abstract
Description
[0001] This application claims the priority of Chinese Patent Application No. 2023106412095 filed on May 31, 2023. This application cites the entire text of the above Chinese Patent Application. Technical Field
[0002] The present invention relates to a conjugate, a pharmaceutical composition and application thereof. Background Art
[0003] Bifunctional degradation:
[0004] Under physiological conditions, proteins in the body are regulated by transcription, translation, and post-translational modification. Once regulatory dysfunction or failure occurs, it may lead to a variety of diseases including cancer. Traditional small molecule therapies inhibit enzymes or receptors by binding compounds to active sites or to allosteric sites.
[0005] Currently, another technology targeting these drug targets is to use bifunctional protein degradation: bifunctional molecules bind to the target protein and an additional protein (usually an E3 ubiquitin ligase) that marks the target protein for natural degradation, and then degrade the target protein through the natural degradation mechanism in the body, thereby achieving the purpose of downregulating the expression level of the target protein. The principles and methods of using this technology for potential disease treatment have been described in many papers and will not be repeated here.
[0006] YAP / TAZ / TEAD signaling pathway and its physiological functions:
[0007] Normal growth, tissue repair and remodeling of tissue cells are subject to precise regulation and a regulatory balance of transcriptional activity. Transcriptional activity is regulated by many signaling pathways, one of which is the Hippo signaling pathway. Genetic studies in fruit flies and mammals have shown that the Hippo signaling pathway is a conserved and important signaling pathway composed of a series of kinases, such as MST1 / 2 and LATS1 / 2, which are responsible for regulating the transcription factor YAP / TAZ.
[0008] When the Hippo signaling pathway is in an active and excited state, YAP / TAZ is phosphorylated and exists in the cytoplasm, or is degraded. When the Hippo signaling pathway is in an inactive and non-excited state, YAP / TAZ will transpose to the nucleus and bind to other transcription factors, the so-called TEAD family proteins, TEAD1, TEAD2, TEAD3 and TEAD4. The YAP / TAZ-TEAD complex promotes the transcription of downstream genes and regulates cell proliferation, death and differentiation. YAP and TAZ can also bind to other factors, and TEAD is widely considered to be the most important regulatory factor for cell growth and tumor growth.
[0009] High activity of the YAP / TAZ-TEAD complex caused by high activation of YAP / TAZ has been found in many human cancers. In these cancers, the expression and protein levels of YAP / TAZ in the nucleus are increased, for example, breast cancer, lung cancer, ovarian cancer, colorectal cancer, pancreatic cancer, prostate cancer, gastric cancer, esophageal cancer, liver cancer, etc. Gene mutations in the Hippo signaling pathway are rare in normal tissue cells, but a large number of mutations have been found in cancer tissue cells, such as mutations in NF2 and LATS1 / 2, which make these proteins no longer function normally, resulting in increased activity of the YAP-TEAD complex, especially in malignant pleural mesothelioma (MPM), the cell growth of malignant pleural mesothelioma depends on the activity of YAP / TAZ-TEAD.
[0010] In addition, the activation of YAP / TAZ-TEAD in tumor cells leads to resistance to chemotherapy drugs and targeted drugs, such as BRAF, MEK, EGFR, and KRAS small molecules. These indicate that inhibiting the activity of YAP / TAZ-TEAD by combined therapy can improve efficacy and reduce tumor resistance. Combination therapy with small molecule targeted drugs can prevent tumor cells from escaping immune surveillance, and inhibiting the activity of YAP can also activate the immune system.
[0011] Disruption of YAP / TAZ-TEAD protein-protein interactions can block the Hippo signaling pathway. Summary of the invention
[0012] The present invention aims to solve the technical problem that there are few types of drugs that inhibit YAP / TAZ-TEAD. To this end, the present invention provides a conjugate, a pharmaceutical composition thereof and its application. This type of compound has good anti-proliferation activity in sensitive cell lines NCI-H2052 cells, MSTO-1H cells and A172 cells.
[0013] The present invention provides a compound as shown in Formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, or a solvate of a pharmaceutically acceptable salt thereof,
[0014] ALM
[0015] I
[0016] in,
[0017] A is
[0018]
[0019] L is composed of one or more of the following structures: a single bond, -O-, C1-10 Alkylene, C 1-10 Heteroalkylene, C 3-10 Cycloalkylene, 3-10 membered heterocycloalkylene, k Substituted C 3-10 Cycloalkylene and one or more R k Substituted 3-10 membered heterocycloalkylene; the heteroatoms of the heterocycloalkylene are selected from one, two or three of N, O and S, and the number of heteroatoms is 1, 2 or 3; the heteroatoms of the heteroalkylene are selected from one, two or three of N, O and S, and the number of heteroatoms is an integer of 1-10;
[0020] Each R k Independently for C 1-6 alkyl;
[0021] M is
[0022]
[0023]
[0024] X 1 , X 2 , X 3 and X 4 are independently a single bond, CH2, O, C(O) or NH;
[0025] R 1 , R 2 , R 3 and R 4 are independently hydrogen, C 1-6 Alkyl or halogen.
[0026] In a preferred embodiment, in the compound of formula I, its solvate, its pharmaceutically acceptable salt or the solvate of its pharmaceutically acceptable salt, certain groups have the following definitions, and the definitions of the unmentioned groups are as described in any embodiment of the present invention (the content of this paragraph is hereinafter referred to as "in a preferred embodiment").
[0027] In a preferred embodiment, L is composed of one or more of the following structures: a single bond, -O-, C 1-10 Alkylene, C 1-10 Heteroalkylene, C 3-10 Cycloalkylene and 3-10 membered heterocycloalkylene; the heteroatoms of the heterocycloalkylene are selected from one, two or three of N, O and S, and the number of heteroatoms is 1, 2 or 3; the heteroatoms of the heteroalkylene are selected from one, two or three of N, O and S, and the number of heteroatoms is an integer of 1-10;
[0028] In a preferred embodiment, A is
[0029] In a preferred embodiment, A is
[0030] In a preferred embodiment, in L, the C 1-10 The alkylene group is a straight chain alkylene group.
[0031] In a preferred embodiment, in L, the C 1-10 Alkylene is C 1-6 Alkylene.
[0032] In a preferred embodiment, in L, the C 1-10 The alkylene group is For example
[0033] In a preferred embodiment, in L, the C 1-10 The heteroatom of the heteroalkylene group is selected from one or both of N and O, and the number of heteroatoms is 1, 2 or 3; for example, the C 1-10 The heteroatom of the heteroalkylene group is N or O.
[0034] In a preferred embodiment, in L, the C 1-10 The heteroatom of the heteroalkylene group is O, and the number of heteroatoms is 1, 2 or 3.
[0035] In a preferred embodiment, in L, the C 1-10 Heteroalkylene is a straight chain heteroalkylene.
[0036] In a preferred embodiment, in L, the C 1-10 The heteroalkylene group is m is 0, 1, 2, 3 or 4; for example
[0037] In a preferred embodiment, in L, the C 1-10 The heteroatom of the heteroalkylene group is N, and the number of heteroatoms is 1, 2 or 3. For example, the C 1-10 The heteroalkylene group is t is 1, 2, 3, 4 or 5, for example
[0038] In a preferred embodiment, in L, the C 3-10 Cycloalkylene is cyclopropylene, cyclobutylene, cyclopentylene or cyclohexylene, for example cyclohexylene, for example
[0039] In a preferred embodiment, in L, the C3-10 Cycloalkylene is cyclobutylene or cyclohexylene, for example Another example
[0040] In a preferred embodiment, in L, the one or more R k Substituted C 3-10 C in cycloalkylene 3-10 Cycloalkylene is cyclopropylene, cyclobutylene, cyclopentylene or cyclohexylene, for example cyclobutylene or cyclohexylene, for example Another example
[0041] In a preferred embodiment, in L, the 3-10 membered heterocycloalkylene group is a 3-6 membered heterocycloalkylene group.
[0042] In a preferred embodiment, in L, the heteroatom of the 3-10 membered heterocycloalkylene group is N, and the number of the heteroatoms is 1, 2 or 3.
[0043] In a preferred embodiment, in L, the 3-10 membered heterocycloalkylene group is a piperidinylene group or a piperazinylene group, for example
[0044] In a preferred embodiment, in L, the one or more R k The 3-10-membered heterocycloalkylene group in the substituted 3-10-membered heterocycloalkylene group is a 3-6-membered heterocycloalkylene group.
[0045] In a preferred embodiment, in L, the one or more R k The heteroatom of the 3- to 10-membered heterocycloalkylene group in the substituted 3- to 10-membered heterocycloalkylene group is N, and the number of the heteroatoms is 1, 2 or 3.
[0046] In a preferred embodiment, in L, the one or more R k The 3-10 membered heterocycloalkylene in the substituted 3-10 membered heterocycloalkylene is piperidinylene or piperazinylene, for example
[0047] In a preferred embodiment, R k In the C 1-6 Alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, for example methyl.
[0048] In a preferred embodiment, in L, the one or more R k The substituted 3-10 membered heterocycloalkylene is For example
[0049] In a preferred embodiment, R 1 , R 2 , R 3 and R 4 In the C 1-6 Alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, for example methyl.
[0050] In a preferred embodiment, R 1 , R 2 , R 3 and R 4 wherein the halogen is independently fluorine, chlorine, bromine or iodine, for example fluorine or chlorine.
[0051] In a preferred embodiment,
[0052] L is -L 1 -Y 1 -L 2 -Y 2 -L 3 -Y 3 -L 4 -L 5 -, where L 1 Connect with A, L 5 Connect with M;
[0053] Y 1 , Y 2 and Y 3 are independently single bonds, C 3-10 Cycloalkylene, 3-10 membered heterocycloalkylene, one or more R k Substituted C 3-10 Cycloalkylene or one or more R k Substituted 3-10 membered heterocycloalkylene;
[0054] L 1 For a single key, or C 1-10 Alkylene;
[0055] L 2 for C 1-10 Alkylene or p1 and p2 are independently t is 1, 2, 3, 4 or 5;
[0056] L 3 is a single bond, -O-, C 1-10 Alkylene, t is 1, 2, 3, 4 or 5, m is 0, 1, 2, 3 or 4;
[0057] L 4 For a single key, or C1-10 Alkylene;
[0058] L 5 For a single key, or C 1-10 Alkylene.
[0059] In a preferred embodiment,
[0060] L is -L 1 -Y 1 -L 2 -Y 2 -L 3 -Y 3 -L 4 -L 5 -, where L 1 Connect with A, L 5 Connect with M;
[0061] Y 1 , Y 2 and Y 3 are independently single bonds, C 3-10 Cycloalkylene or 3-10 membered heterocycloalkylene;
[0062] L 1 For a single key, or C 1-10 Alkylene;
[0063] L 2 for or C 1-10 Alkylene;
[0064] L 3 -O-, C 1-10 Alkylene or m is 0, 1, 2, 3 or 4; L 4 For a single key, or C 1-10 Alkylene;
[0065] L 5 For a single key, or C 1-10 Alkylene.
[0066] In a preferred embodiment, L is any of the following:
[0067] Solution 1: L is -L 1 -Y 1 -L 2 -Y 2 -L 3 -Y 3 -L 4 -L 5 -, where L 1Connect with A, L 5 Connect with M;
[0068] L 1 is a single bond;
[0069] Y 1 is a single bond or C 3-10 Cycloalkylene;
[0070] L 2 for or C 1-10 Alkylene;
[0071] Y 2 is a 3-10 membered heterocycloalkylene group;
[0072] L 3 -O- or C 1-10 Alkylene;
[0073] Y 3 is a 3-10 membered heterocycloalkylene group;
[0074] L 4 For a single key or L 5 is a single bond or C 1-10 Alkylene;
[0075] Solution 2: L is -L 1 -Y 1 -L 2 -Y 2 -L 3 -Y 3 -L 4 -L 5 -, where L 1 Connect with A, L 5 Connect with M;
[0076] Y 1 , Y 2 and Y 3 is a single bond;
[0077] L 1 for or C 1-10 Alkylene;
[0078] L 2 for or C 1-10 Alkylene;
[0079] L 3 C 1-10 Alkylene or m is 0, 1, 2, 3 or 4; L 4 For a single key, or C1-10 Alkylene;
[0080] L 5 For a single key, or C 1-10 Alkylene.
[0081] In a preferred embodiment, L is the following embodiment 3:
[0082] Solution 3: L is -L 1 -Y 1 -L 2 -Y 2 -L 3 -Y 3 -L 4 -L 5 -, where L 1 Connect with A, L 5 Connect with M;
[0083] L 1 is a single bond;
[0084] Y 1 C 3-10 Cycloalkylene;
[0085] L 2 for
[0086] Y 2 and Y 3 is a single bond;
[0087] L 3 for t is 1, 2, 3, 4, or 5;
[0088] L 4 For a single key, or C 1-10 Alkylene;
[0089] L 5 For a single key, or C 1-10 Alkylene.
[0090] In a preferred embodiment, L is the following embodiment 4:
[0091] Solution 4: L is -L 1 -Y 1 -L 2 -Y 2 -L 3 -Y 3 -L 4 -L 5 -, where L 1 Connect with A, L 5 Connect with M;
[0092] L 1 For a single key or
[0093] Y 1 is a single bond;
[0094] L 2 C 1-10 Alkylene or p1 and p2 are independently t is 1, 2, 3, 4 or 5; Y 2 is a single bond or C 3-10 Cycloalkylene;
[0095] L 3 is a single bond, -O- or C 1-10 Alkylene;
[0096] Y 3 is a 3-10 membered heterocycloalkylene group or is represented by one or more R k Substituted 3-10 membered heterocycloalkylene;
[0097] L 4 For a single key, or C 1-10 Alkylene;
[0098] L 5 For a single key, or C 1-10 Alkylene.
[0099] In a preferred embodiment, L is
[0100] Preferably, L is
[0101] In a preferred embodiment, L is
[0102] In a preferred embodiment, L is
[0103] Preferably, L is
[0104] The "1" bit is connected to A, and the "2" bit is connected to M.
[0105] In a preferred embodiment, L is Preferably, L is The "1" bit is connected to A, and the "2" bit is connected to M.
[0106] In a preferred embodiment, L is
[0107] Preferably, L is
[0108] The "1" bit is connected to A, and the "2" bit is connected to M.
[0109] In a preferred embodiment, X 1 is O or NH.
[0110] In a preferred embodiment, X 2 is C(O).
[0111] In a preferred embodiment, X 3 is O or NH; for example, X 3 is O.
[0112] In a preferred embodiment, X 4 is a single bond or CH2, for example a single bond.
[0113] In a preferred embodiment, R 1 For hydrogen.
[0114] In a preferred embodiment, R 2 is a halogen such as fluorine.
[0115] In a preferred embodiment, R 3 C 1-6 Alkyl or halogen, such as methyl or chlorine.
[0116] In a preferred embodiment, R 3 C 1-6 An alkyl group, such as a methyl group.
[0117] In a preferred embodiment, R 4 For hydrogen.
[0118] In a preferred embodiment, in M, for For example
[0119]
[0120] In a preferred embodiment, in M, for For example
[0121]
[0122] In a preferred embodiment, in M, for For example
[0123]
[0124] In a preferred embodiment, in M, for Preferably,
[0125] In a preferred embodiment, in M, for For example
[0126]
[0127] In a preferred embodiment, M is
[0128] In a preferred embodiment, A is
[0129] L is
[0130] L 1 For a single key, or C 1-10 Alkylene;
[0131] L 2 for or C 1-10 Alkylene;
[0132] L 3 -O-, C 1-10 Alkylene, t is 1, 2, 3, 4 or 5; m is 0, 1, 2, 3 or 4;
[0133] L 4 For a single key, or C 1-10 Alkylene;
[0134] L 5 For a single key, or C 1-10 Alkylene;
[0135] M is
[0136] X 1 is O or NH;
[0137] X 3 is O or NH;
[0138] R 1 and R 3 are independently hydrogen, C 1-6 Alkyl or halogen.
[0139] In a preferred embodiment, the compound as shown in formula I is any of the following compounds:
[0140]
[0141]
[0142]
[0143]
[0144]
[0145]
[0146]
[0147]
[0148]
[0149] The present invention also provides a compound, a solvate thereof, a pharmaceutically acceptable salt thereof, or a solvate of a pharmaceutically acceptable salt thereof, wherein the compound is any of the following compounds:
[0150]
[0151]
[0152] R a =H, TBS, TBDPS or Me;
[0153] R b =CN, CO2H, CO2Me, CO2Et, CO2tBu, CO2NH2, CO2NHMe or CO2NHEt.
[0154] In a preferred embodiment, for
[0155] The present invention also provides a pharmaceutical composition comprising:
[0156] (1) The compound of formula I as described in any one of the present invention, its solvate, its pharmaceutically acceptable salt or its solvate of a pharmaceutically acceptable salt;
[0157] (2) Pharmaceutically acceptable excipients.
[0158] The present invention also provides use of any of the above compounds as shown in Formula I, their solvates, their pharmaceutically acceptable salts or solvates of their pharmaceutically acceptable salts, or the above pharmaceutical compositions in the preparation of drugs for preventing and / or treating cancer.
[0159] In a preferred embodiment, the cancer is caused by abnormal expression of YAP / TAZ.
[0160] In a preferred embodiment, the cancer is lung cancer, gastric adenocarcinoma, mesothelioma, solid tumor or glioblastoma.
[0161] In a preferred embodiment, the cancer is lung cancer, gastric adenocarcinoma, mesothelioma or solid tumor.
[0162] The present invention also provides a method for preventing and / or treating cancer, comprising administering to a patient a therapeutically effective amount of a compound as shown in Formula I as described in any one of the present invention, a solvate thereof, a pharmaceutically acceptable salt thereof, or a solvate of a pharmaceutically acceptable salt thereof.
[0163] In a preferred embodiment, the cancer is caused by abnormal expression of YAP / TAZ.
[0164] In a preferred embodiment, the cancer is lung cancer, gastric adenocarcinoma, mesothelioma or solid tumor.
[0165] In a preferred embodiment, the cancer is lung cancer, gastric adenocarcinoma, mesothelioma, solid tumor or glioblastoma.
[0166] Without violating the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.
[0167] The reagents and raw materials used in the present invention are commercially available.
[0168] The positive and progressive effect of the present invention is that the compound of the present invention has good anti-proliferation activity on sensitive cell lines NCI-H2052 cells, SF-268 cells and A172 cells.
[0169] Unless otherwise specified, the terms used in the present invention have the following meanings:
[0170] It will be understood by those skilled in the art that the structural formulas used in the present invention to describe groups are based on the conventions used in the art. It means that the corresponding group is connected to other fragments and groups in the compound through this site.
[0171] As used herein, a substituent may be preceded by a single dash "-" to indicate that the named substituent is connected to the parent moiety by a single bond. When the linking group listed in the present invention does not specify its connection direction, its connection direction is connected in the same direction as the reading order from left to right. For example, the linking group L in ALM is -L 1 -Y 1 -L 2 -Y 2 -L 3 -Y 3 -L 4 -L 5 -, at this time -L 1 -Y 1 -L 2 -Y 2 -L 3 -Y 3 -L 4 -L 5 - Connect A and M in the same direction as reading from left to right to form AL 1 -Y 1 -L 2 -Y 2 -L 3 -Y 3 -L 4 -L 5 -M. Specifically in the present invention, for example, L is , it means that the alkylene end is connected to A through a single bond, rather than the carbonyl group being connected to A through a single bond.
[0172] If a linking group is represented as a "single bond", the structures on both sides of the linking group are directly connected by a single bond, such as -L 1 -Y 1 -L 2 -Y 2 -L 3 -Y 3 -L 4 -L 5 -, when Y 1 , Y 2 and Y 3 When it is a single bond, -L 1 -Y 1 -L 2 -Y 2 -L 3 -Y 3 -L 4 -L 5 - is -L 1 -L 2 -L 3 -L 4 -L 5 -.
[0173] The term "pharmaceutically acceptable" means that salts, solvents, excipients, etc. are generally non-toxic, safe, and suitable for use by patients. The "patient" is preferably a mammal, more preferably a human.
[0174] The term "pharmaceutically acceptable salt" refers to a salt prepared from a compound of the present invention and a relatively nontoxic, pharmaceutically acceptable acid or base. When the compound of the present invention contains a relatively acidic functional group, a base addition salt can be obtained by contacting the neutral form of such compound with a sufficient amount of a pharmaceutically acceptable base in a pure solution or a suitable inert solvent. When the compound of the present invention contains a relatively basic functional group, an acid addition salt can be obtained by contacting the neutral form of such compound with a sufficient amount of a pharmaceutically acceptable acid in a pure solution or a suitable inert solvent. The pharmaceutically acceptable acid includes an inorganic acid. The pharmaceutically acceptable acid includes an organic acid. When the compound of the present invention contains relatively acidic and relatively basic functional groups, it can be converted into a base addition salt or an acid addition salt. For details, see Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science 66: 1-19 (1977), or Handbook of Pharmaceutical Salts: Properties, Selection, and Use (P. Heinrich Stahl and Camille G. Wermuth, ed., Wiley-VCH, 2002).
[0175] The term "solvate" refers to a substance formed by combining a compound of the present invention with a stoichiometric or non-stoichiometric amount of a solvent. The solvent molecules in the solvate may be present in an ordered or non-ordered arrangement.
[0176] The "pharmaceutically acceptable salt" and "solvate" in the term "pharmaceutically acceptable salt solvate" as described above refer to substances formed by combining the compounds of the present invention with 1. relatively non-toxic, pharmaceutically acceptable acids or bases prepared 2. stoichiometric or non-stoichiometric solvents.
[0177] The terms "compound", "pharmaceutically acceptable salt", "solvate" and "solvate of a pharmaceutically acceptable salt" may exist as a single tautomer or a mixture thereof if tautomers exist, preferably in a form in which the more stable tautomer is the main tautomer.
[0178] The term "halogen" refers to fluorine, chlorine, bromine or iodine.
[0179] The term "alkyl" refers to a straight or branched chain alkyl group having a specified number of carbon atoms. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, and the like.
[0180] The term "alkylene" refers to a substituent formed by eliminating two hydrogen atoms from a saturated straight or branched alkane having a specified number of carbon atoms. The two hydrogen atoms eliminated may be on the same carbon atom or on different carbon atoms (e.g., the two hydrogen atoms eliminated are on the carbon atoms at the two ends). Thus, C1 alkylene (i.e., methylene) refers to -CH2-, and C2 alkylene (i.e., ethylene) refers to -CH2-CH2- or -CH(CH3)-.
[0181] The term "heteroalkylene" refers to a substituent formed by removing two hydrogen atoms from a heteroalkane. The two hydrogen atoms removed can be on the same atom or on different atoms (for example, the two valence atoms are on the two ends). Among them, "heteroalkane" refers to a saturated straight-chain or branched alkane parent structure in which the carbon atoms at a certain position are replaced by heteroatoms and have a specified number of carbon atoms (for example, C1 to C 10 ), a specified number of heteroatoms (e.g., 1, 2, or 3), and a specified type of heteroatoms (one or more of N, O, and S). Heteroalkylene includes, but is not limited to wait.
[0182] The term "cycloalkylene" refers to a substituent formed by removing two hydrogen atoms from a cycloalkane. The two hydrogen atoms removed can be on the same ring carbon atom or on different ring carbon atoms. Here, "cycloalkane" refers to a substituent having a specified number of ring carbon atoms (e.g., C3 to C 10 ), saturated monocyclic, bridged or spirocyclic alkanes whose ring atoms consist only of carbon atoms. For example, C3 cycloalkylene (i.e., cyclopropylene) can be C6 cycloalkylene (i.e. cyclohexylene) can be
[0183] The term "heterocycloalkylene" refers to a substituent formed by eliminating two hydrogen atoms from a heterocycloalkane. The two hydrogen atoms eliminated may be on the same ring atom or on different ring atoms. Among them, "heterocycloalkane" refers to a saturated cycloalkane parent structure in which the ring carbon atom at a certain position is replaced by a heteroatom, and has a specified number of ring atoms (e.g., 3-10 members), a specified number of heteroatoms (e.g., 1, 2, or 3), and a specified type of heteroatom (one or more of N, O, and S). "Heterocycloalkane" may be a monocyclic ring, a bridged ring, or a spirocyclic ring, and each ring is saturated. Heterocycloalkylene includes, but is not limited to, piperidinylene or piperazinylene, for example
[0184] The term "pharmaceutically acceptable excipients" refers to excipients and additives used in the production of drugs and the preparation of prescriptions, and is all substances contained in drug preparations except the active ingredients. Please refer to the Pharmacopoeia of the People's Republic of China (2015 Edition) Part IV, or Handbook of Pharmaceutical Excipients (Raymond C Rowe, 2009 Sixth Edition).
[0185] The term "treat" refers to therapeutic treatment. When referring to a specific condition, treatment means: (1) ameliorating the disease or one or more biological manifestations of the condition, (2) interfering with (a) one or more points in the biological cascade leading to or causing the condition or (b) one or more biological manifestations of the condition, (3) ameliorating one or more symptoms, effects, or side effects associated with the condition or one or more symptoms, effects, or side effects associated with the condition or its treatment, or (4) slowing the progression of the condition or one or more biological manifestations of the condition.
[0186] The term "prevent" refers to the reduction of the risk of acquiring or developing a disease or disorder.
[0187] The term "therapeutically effective amount" refers to an amount of a compound that is sufficient to effectively treat a disease or condition described herein when administered to a patient."Therapeutically effective amount" will vary depending on the compound, the condition and its severity, and the age of the patient to be treated, but can be adjusted as needed by those skilled in the art.
[0188] The term "patient" refers to any animal that is about to or has been administered the compound or composition according to the embodiments of the present invention, preferably a mammal, and most preferably a human. The term "mammal" includes any mammal. Examples of mammals include, but are not limited to, cattle, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, humans, etc., with humans being the most preferred. BRIEF DESCRIPTION OF THE DRAWINGS
[0189] Figure 1 : NOESY identification diagram of compound 64-4a;
[0190] Figure 2 : NOESY identification diagram of compound 64-4b. DETAILED DESCRIPTION
[0191] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.
[0192] Example 1: Preparation of Intermediate a
[0193]
[0194]
[0195]
[0196] Step 1: Compound a-1 (1000g, 5.18mol) was dissolved in tetrahydrofuran (16.6L), cooled to -75°C under nitrogen protection, and lithium diisopropylamide (2M, 2.85L) was added dropwise. After the addition was completed, the reaction was stirred at -78°C for 2 hours under nitrogen protection. Trimethylsilyl chloride (844g, 7.77mol) was added dropwise at -78°C, and the reaction was stirred at -78°C for 1 hour under nitrogen protection. Then lithium diisopropylamide (2M, 2.85L) was added dropwise, and the reaction was stirred at -78°C for 2 hours under nitrogen protection. Finally, N,N-dimethylformamide (681g, 9.33mol) was added at -78°C, and the reaction was stirred at -78°C for 1 hour under nitrogen protection. TLC (PE) showed that the reaction was complete. Acetic acid (1000mL) / water (4662mL) solution was added to quench. After the addition, the organic solution (ethyl acetate, 1000 mL x 2) was used for extraction. The combined organic phases were washed three times with saturated brine (1000 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain an orange-red oily compound a-2 (1.83 kg, crude). 1 H NMR (400MHz, CDCl3) δ 10.29 (d, J = 1.2 Hz, 1H), 7.18 (dd, J = 8.0, 1.6 Hz, 1H), 0.40 (t, J = 1.6 Hz, 9H).
[0197] Step 2: Dissolve compound a-2 (1.83 kg, crude) in tetrahydrofuran (1.8 L), cool to 0°C, and add sodium methoxide (337 g, 6.24 mol) in batches. After the addition is complete, stir the reaction solution at 0°C for 3 hours. Take a sample to detect the reaction, TLC (PE / EA=10 / 1, R f =0.2) showed that the reaction was complete. Water (3L) was added to quench, and ethyl acetate (1Lx2) was used for extraction. The combined organic phases were washed three times with saturated brine (1L), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was purified by silica gel column chromatography (PE:EA=100:1~20:1) to obtain a light orange solid compound a-3 (180g, Y:12%). 1 H NMR (400MHz, CDCl3) δ10.34 (s, 1H), 7.02 (dd, J = 8.0, 2.4Hz, 1H), 6.69 (dd, J = 10.0, 2.0Hz, 1H), 3.92 (s, 3H).
[0198] Step 3: Compound a-3 (180g, 772mmol) was dissolved in acetonitrile (1.8L), and N-chlorosuccinimide (206g, 1.54mol) and p-toluenesulfonic acid (212g, 1.24mol) were added under nitrogen protection, and the reaction was carried out at 25°C for 16 hours. When the temperature was lower than 20°C, a large amount of solid precipitated from the reaction solution. TLC (PE:EA=10:1) showed that the reaction was complete. The reaction solution was poured into a saturated sodium bicarbonate solution (1.5L) for quenching, and ethyl acetate (1Lx2) was added for extraction. The organic phases were combined and washed three times with saturated brine (1L), and the organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate=100 / 1~20 / 1) to obtain a light yellow solid compound a-4 (145g, Y:70%). 1 H NMR (400MHz, DMSO-d6) δ10.15 (s, 1H), 7.50 (d, J = 11.2Hz, 1H), 3.91 (s, 3H).
[0199] Step 4: Dissolve compound a-4 (145g, 542mmol) in dichloromethane (400mL), cool to -75°C, and drop boron tribromide dichloromethane solution (2M, 966mL). After the addition is complete, the reaction is stirred at -78°C for 0.5 hours under nitrogen protection. Samples are taken to detect the reaction, and TLC (PE:EA=10:1) shows that the reaction is complete. While stirring, slowly pour the reaction solution into ice water (3L) to quench, and extract with dichloromethane (1L×2). The combined organic phases are washed three times with saturated brine (1L). The organic phase is dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to obtain a crude product. The crude product is purified by silica gel column chromatography (PE / EA=100 / 1~20 / 1). White solid compound a-5 (87g, Y: 63%) is obtained. 1 H NMR (400MHz, DMSO-d6) δ12.01 (brs, 1H), 10.16 (s, 1H), 7.14 (d, J = 10.4Hz, 1H).
[0200] Step 5: Dissolve compound a-5 (20.0 g, 78.9 mmol) in acetonitrile (400 mL), add diisopropylethylamine (20.4 g, 157.8 mmol) and methyl bromophenylacetate (21.7 g, 94.7 mmol) in sequence under nitrogen protection, and gradually heat to 85 ° C for 16 hours. TLC (PE: EA = 20: 1) shows that the raw material is completely reacted. After direct vacuum concentration, silica gel column chromatography (EA / PE = 1 / 16) is purified to obtain 27.0 g of yellow solid compound a-6 (27.0 g, Y: 85%). 1H NMR (400MHz, DMSO-d6) δ7.68-7.62(m,1H),7.55-7.50(m,1H),7.45-7.38(m,4H),6.92(d,J=7.2Hz,0 .5H), 6.11(d,J=8.8Hz,0.5H), 5.58(d,J=8.8Hz,0.5H), 5.41(d,J=7.6Hz,0.5H), 3.71-3.64(m,3H).
[0201] Step 6: Dissolve compound a-6 (27.0 g, 67.5 mmol) in dichloromethane (300 mL), cool to 0 ° C under nitrogen protection, add triethylsilyl hydride (39.2 g, 337.5 mmol) and boron trifluoride ether (32.1 g, 135.0 mmol) dropwise into the system, heat to 25 ° C, and react for 16 hours. After the reaction is complete, pour into saturated sodium bicarbonate solution, extract with dichloromethane (200 mL × 3), combine the organic phases, wash with saturated brine (20 mL), dry the organic phase with anhydrous sodium sulfate, filter, concentrate the filtrate under reduced pressure, and purify it by silica gel column chromatography (EA: PE = 1: 20) to obtain 20.8 g of yellow solid compound. Chiral separation (chiral column model: Chiralpak AD-3100×3.0mm 3.0um, solvent: isopropanol, flow rate: 2.0ml / min, a-7a (t=1.01min), a-7b (t=0.87min) gave compound a-7a (10.1g, Y: 39%). 1 H NMR (400MHz, DMSO-d6) δ7.56-7.53(m,2H),7.44-7.34(m,3H),6.83(d,J=8.8Hz,1H),4.22-4.15(m,1H),3.77(s,3H),3.58-3.51(m,1H).
[0202] Step 7: Dissolve compound a-7a (1 g, 2.81 mmol) in methanol (10 mL), cool to 0 ° C under nitrogen protection, add sodium borohydride (531 mg, 14.0 mmol) in batches, and react at 0 ° C for 2 hours. TLC (PE: EA = 10: 1) shows that the raw material is completely reacted. Pour the reaction solution into saturated ammonium chloride (20 mL) at 0 ° C to quench the reaction, add ethyl acetate (30 mL × 3) to extract, combine the organic phases, wash with saturated brine (30 mL), dry the organic phase with anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure to obtain compound a-8 (800 mg, crude).
[0203] Step 8: Dissolve compound a-8 (800 mg, 2.2 mmol) in toluene (10 mL), add [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (160 mg, 223 μmol), biboric acid pinacol ester (1.14 g, 4.5 mmol) and potassium acetate (660 mg, 6.7 mmol) in sequence under nitrogen protection, heat to 90 ° C for 16 hours, LCMS shows that the raw material is completely reacted. Cool to 25 ° C, directly concentrate under reduced pressure, and purify by silica gel column chromatography (EA: PE = 1: 20) to obtain compound a-9 (400 mg, Y: 44%). LC-MS m / z (ESI): 405 [M + H] + .
[0204] Step 9: Compound a-10 (225.0 g, 0.74 mol) was dissolved in tetrahydrofuran (2.25 L), cooled to -70 ° C, and under nitrogen protection, a tetrahydrofuran solution of isopropyl magnesium chloride (523 mL, 2 M) was added dropwise, and the mixture was reacted at -70 ° C for 1 hour. 2-Methacrylic anhydride (161.2 g, 1.05 mol) was added, and the mixture was naturally heated to 10 ° C for 1 hour. TLC (PE: EA = 20: 1) showed that the raw material was completely reacted. Water (4.5 L) was slowly added to the reaction solution, and ethyl acetate (2.0 L × 3) was added for extraction. The organic phases were combined and washed with saturated brine (2500 mL), and the organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by silica gel column chromatography (EA: PE = 1: 10) to obtain a light yellow yellow compound a-11 (292 g, Y: 80%).
[0205] Step 10: Dissolve compound a-11 (170.0 g, 0.70 mol) in dichloromethane (255 mL), add trifluoromethanesulfonic acid (595 mL), and react at 40°C for 16 hours under nitrogen protection. TLC (PE: EA = 10: 1) shows that the raw material has reacted completely. Cool the system to room temperature, slowly pour into an ice-water solution of saturated sodium carbonate (5 L), extract with ethyl acetate (1.5 L × 3), combine the organic phases and wash with saturated brine (1000 mL × 2), dry the organic phase with anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. Purify by silica gel column chromatography (EA: PE = 1: 10 to 1: 5) to obtain yellow solid compound a-12 (127 g, Y: 74%).
[0206] Step 11: Place triethylamine (626.2 g, 6.2 mol) in a 3L reaction bottle, cool the system to 0°C, and slowly drop formic acid (713.0 g, 15.5 mol). After the dropwise addition is completed, stir at 15°C for 0.5 h. Add (S,S)-N-(p-toluenesulfonyl)-1,2-diphenylethanediamine (p-isopropylbenzene) ruthenium (II) chloride (13.5 g, 21.7 mmol) and a-12 (150.0 g, 0.62 mol) in sequence, and stir at 15°C for 1 hour under nitrogen protection until the reaction system is dissolved. Heat to 30°C and react for 16 hours. TLC (PE:EA=10:1, phosphomolybdic acid color development) shows that the raw materials are completely reacted. The reaction solution was slowly poured into water (1700 mL), extracted with ethyl acetate (1600 mL×3), the combined organic phases were washed with saturated brine (400 mL×2), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by silica gel column chromatography (EA:PE=1:100~1:10) to obtain a light yellow solid compound a-13 (136.1 g, Y: 90%).
[0207] Step 12: Dissolve compound a-13 (272.0 g, 1.12 mol) in anhydrous dichloromethane (2720 mL), cool to 0 ° C, add imidazole (152.3 g, 2.24 mol) and tert-butyldimethylsilyl chloride (506 g, 3.36 mol) in turn, and react at room temperature for 16 hours under nitrogen protection. TLC (PE) shows that the raw material has reacted completely. The solid is filtered and rinsed with ethyl acetate (200 mL × 2). After the filtrate is concentrated under reduced pressure, it is purified by silica gel column chromatography (EA: PE = 1: 40) to obtain a colorless oil compound a-14 (359.7 g, Y: 89%). 1 H NMR (400MHz, CDCl3) δ7.14(d,J=0.8Hz,1H),7.02(dt,J=8.5,0.7Hz,1H),5.10(d,J=5.5Hz,1H),2 .85-2.70(m,2H),2.42-2.35(m,1H),1.13(d,J=6.9Hz,3H),0.89-0.85(m,9H),0.15-0.04(m,6H).
[0208] Step 13: Compound a-14 (105.0 g, 0.29 mol) was dissolved in tetrahydrofuran (3.15 L), cooled to -70 ° C, and butyl lithium (117 mL, 2.5 M, 0.29 mol) was added dropwise under nitrogen protection. The mixture was reacted at -70 ° C for 1 hour, and carbon dioxide gas was introduced and reacted at -70 ° C for 0.5 hour. TLC (EA: PE = 1: 100) showed that the raw material reaction was complete. Saturated ammonium chloride (2000 mL) was added dropwise to quench, and ethyl acetate (500 mL × 3) was used for extraction. The combined organic phases were washed with saturated brine (200 mL), and the organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Purification by silica gel column chromatography (EA: PE = 1: 40) gave an off-white solid a-15 (56 g, Y: 60%). LC-MS m / z (ESI): 323.1 [MH] - .
[0209] Step 14: n-Butyl lithium (207 mL, 2.5 M) was dissolved in tetrahydrofuran (280 mL), cooled to -70 ° C, and tetramethylethylenediamine (155 mL) was added dropwise under nitrogen protection. The reaction was carried out at -70 ° C for 0.5 hours. Compound a-15 (56.0 g, 172 mmol) was dissolved in tetrahydrofuran (280 mL) and added dropwise to the above reaction solution. The reaction was carried out at -70 ° C for 1 hour. 1,2-dibromotetrafluoroethane (134 g, 517 mmol) was added and the reaction was carried out at -70 ° C for 1 hour. LCMS showed that the raw material was completely reacted. Water (600 mL) was slowly added to the reaction solution, and ethyl acetate (500 mL × 3) was used for extraction. The organic phases were combined and washed with saturated brine (500 mL). The organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain white solid compound a-16 (60.5 g, Y: 87%). LC-MS m / z(ESI):401.0 / 403.0[MH] - .
[0210] Step 15: Compound a-16 (67.2 g, 166 mmol) was dissolved in dichloromethane (670 mL), and diisopropylethylamine (64.6 g, 499 mmol), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (148 g, 333 mmol) and methylamine hydrochloride (22.5 g, 333 mmol) were added in sequence, and the mixture was reacted at room temperature for 4 hours under nitrogen protection. LCMS showed that the raw materials reacted completely. The reaction solution was poured into saturated ammonium chloride (1200 mL) for quenching, extracted with dichloromethane (600 mL×3), the combined organic phases were washed with saturated brine (1000 mL), the organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and purified by silica gel column chromatography (THF:PE=1:4) to obtain white compound a-17 (55 g, Y:79%). 1HNMR (400MHz, CDCl3): δ7.15(s,1H),5.90(s,1H),5.16(d,J=5.6Hz,1H),3.01(d,J=4.8Hz,3H) ,2.85-2.60(m,2H),2.48-2.32(m,1H),1.12(d,J=6.8Hz,3H),0.89(s,9H),0.15-0.05(m,6H). LC-MS m / z(ESI):416.2 / 418.2[M+H] + Chiral analysis (column model: Celluiose-SB, 100*4.6mm, 3um; eluent Hexane-IPA; gradient: isocratic 19 / 1, flow rate: 1ml / min: running time 15.0min; peak time 9.38min).
[0211] Step 16: Dissolve compound a-17 (300 mg, 0.72 mmol) and compound a-9 (466 mg, 1.15 mmol) in toluene (5 mL) and water (1 mL), and add tri(dibenzylideneacetone)dipalladium (99 mg, 0.11 mmol), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (125 mg, 0.22 mmol) and anhydrous potassium carbonate (298 mg, 2.16 mmol) in sequence. React at 110 ° C overnight under nitrogen protection. LCMS shows that the raw material is completely reacted. Cool to 25 ° C, concentrate the reaction solution under reduced pressure, and then chromatograph on a silica gel column (EA: PE = 1: 10 to 1: 1, R f =0.6 and R f =0.5, where R f =0.5 is the target product) to obtain a crude product. The crude product was purified by C18 silica gel column (C18, 40.0 g, gradient: 70-90% MeCN in H2O; flow rate: 30 ml / min: running time 10 min) to obtain compound a-18 (160 mg, Y: 36%). LC-MS (1.5 ml-3.2 min-5-95% B): Rt=1.847, m / z (ESI)): 614.3 / 616.3 [M+H] + .
[0212] Step 17: Dissolve compound a-18 (160 mg, 0.26 mmol) in anhydrous dichloromethane (4 mL), add Dess-Martin periodinant (165 mg, 0.39 mmol) and solid sodium bicarbonate (60 mg, 0.71 mmol) in turn, and react at 25 ° C for 0.5 hours under nitrogen protection. LCMS shows that the raw material is completely reacted. Add saturated sodium thiosulfate aqueous solution (20 mL) to the reaction solution, extract with ethyl acetate (15 mL×2), combine the organic phases and wash with saturated brine (10 mL×2), dry the organic phase with anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure to obtain crude compound a-19 (120 mg, crude). LC-MS m / z (ESI): 612.2 [M+H] + .
[0213] Step 18: Compound a-19 undergoes a reductive amination reaction with trans-4-aminocyclohexylcarboxylic acid ethyl ester hydrochloride in the presence of acetic acid and sodium triacetate borohydride to synthesize compound a-20.
[0214] Step 19: Compound a-20 can undergo hydrolysis reaction in the presence of lithium hydroxide to synthesize compound a.
[0215] Alternatively, step 18: Compound a-19 (390 mg, 0.64 mmol) and trans-4-aminocyclohexanecarboxylic acid methyl ester (200 mg, 1.28 mmol) were dissolved in 1,2-dichloroethane (8 mL), acetic acid (19 mg, 0.32 mmol) was added, and the mixture was reacted at 80°C for 15 hours. Sodium acetate borohydride (270 mg, 1.28 mmol) was added, and LCMS showed that the raw materials were completely reacted. The reaction solution was diluted with water, extracted with dichloromethane (50 mL × 3), the combined organic phases were washed with saturated brine (20 mL × 3), the organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and then purified by C18 reverse phase (ACN:H2O=60%) to obtain yellow solid compound a-20-1 (130 mg, Y: 27%). MS m / z (ESI): 753.4 [M+H] + .
[0216] Step 19: Dissolve compound a-20 (130 mg, 0.17 mmol) in tetrahydrofuran (2 mL), dissolve lithium hydroxide (8.5 mg, 0.35 mmol) in water (1 mL), add to the above system at 0°C, react at room temperature for 2 hours, LCMS shows that the raw material is completely reacted. Adjust the reaction solution to pH = 3 with hydrochloric acid (2M), extract with dichloromethane (50 mL×3), wash the combined organic phases with saturated brine (20 mL×3), dry the organic phase with anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure to obtain a crude product of yellow solid compound a (120 mg, crude). LC-MS m / z (ESI): 739.3 [M+H] + .
[0217] Example 2: Preparation of intermediate b
[0218]
[0219] Step 1: Dissolve triphenylmethylphosphonium bromide (538 g, 1506 mmol) in tetrahydrofuran (1500 mL), add potassium tert-butoxide (135 g, 1204 mmol) under nitrogen protection, react at 25°C for 4 hours, cool the reaction solution to -70°C, dissolve compound b-1 (200 g, 100.4 mmol) in tetrahydrofuran (500 mL) and add dropwise to the reaction solution, warm to 25°C and react for 16 hours, pour the reaction solution into saturated ammonium chloride (2000 mL) to quench, extract with ethyl acetate (700 mL×3), combine the organic phases, wash with saturated brine (2000 mL), dry the organic phase with anhydrous sodium sulfate, filter, concentrate the filtrate under reduced pressure, slurry with n-heptane (2000 mL), filter, and concentrate the filtrate under reduced pressure to obtain a light yellow oily compound b-2 (197 g, Y: 99%). 1 H NMR (400MHz, CDCl3) δ5.79-5.69(m,1H),5.08-4.99(m,2H),4.31-4.20(m,1H),3.42-3.29(m,2H),2.04-1.65(m,4H),1.42(s,9H).
[0220] Step 2: Compound b-2 (197 g, 1000 mmol) was dissolved in dichloromethane (2000 mL), and meta-chloroperbenzoic acid (406 g, 2000 mmol, 85% wt) was added. The mixture was stirred at room temperature for 16 hours. TLC showed that the reaction of the raw materials was complete. The reaction solution was poured into saturated sodium sulfite (2000 mL) for quenching, and extracted with dichloromethane (2000 mL×3). The combined organic phases were washed with saturated sodium carbonate (2000 mL), and the organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a light yellow oily compound b-3 (198 g, Y: 93%).
[0221] Step 3: Dissolve 1-bromo-3,5-difluoroiodobenzene (445 g, 1395 mmol) in toluene (1800 mL), cool to -70°C under nitrogen protection, drop n-butyl lithium (558 ml, 2.5 M, 1395 mmol), stir at -70°C for 0.5 hour (note that solid will precipitate from the system), dissolve compound b-3 (198 g, 930 mmol) in toluene (400 mL) and drop into the reaction solution at -70°C, then Then boron trifluoride etherate (158 g, 1116 mmol) was added dropwise, and the mixture was stirred at -70°C for 0.5 h. LCMS showed that the raw material reaction was complete. The mixture was quenched by adding saturated sodium carbonate (2000 mL), and extracted with ethyl acetate (1000 mL×3). The combined organic phases were washed with saturated brine (2000 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a light yellow oily compound b-4 (368 g, Y: 97%).
[0222] Step 4: Dissolve compound b-4 (368 g, 906 mmol) in dichloromethane (3680 mL), add Dess-Martin (423 g, 997 mmol) in batches at room temperature, and react at room temperature for 16 hours. LCMS shows that the raw material reacts completely, pour the reaction solution into saturated sodium sulfite (3000 mL) to quench, add saturated sodium carbonate (1000 mL) to wash, combine the organic phases and wash with saturated brine (2000 mL), dry the organic phase with anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure to obtain a yellow oily compound (301 g, Y: 82%). Pulp with (PE: EA = 50: 1, 180 mL), filter, and collect the filter cake to obtain an off-white solid b-5 (181 g, Y: 60%). 1HNMR (400MHz, CDCl3): δ7.20-7.12(m,1H),6.88-6.78(m,1H),4.50-4.32(m,1H) ),4.10-3.88(m,2H),3.68-2.42(m,2H),2.31-1.86(m,4H),1.58-1.38(m,9H). LC-MS m / z(ESI):426.2 / 428.1[M+Na] + Chiral analysis (column model: Celluiose-SC, 100*4.6 mm, 3 um; method: 1.0 mL-65% Hexane-35% EtOH-20 min-SB: running time 8.0 min; peak time 2.54 min).
[0223] Step 5: Compound b-5 (121 g, 299 mmol) was dissolved in dichloromethane (600 mL) and n-heptane (600 mL), the reaction solution was cooled to 0°C, phenylmagnesium bromide (299 mL, 897 mmol, 3 mol / L) was added dropwise, and the mixture was reacted at 0°C for 2 hours. LCMS showed that 1 / 4 to 1 / 5 of the raw material remained, the reaction solution was poured into saturated ammonium chloride (2000 mL) for quenching, the organic solvent was removed by concentration under reduced pressure, ethyl acetate (2000 mL) was added, diatomaceous earth was filtered, the organic phases were extracted and combined, washed with saturated brine (1500 mL), the organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a yellow oily product b-6 (139 g, Y: 96%).
[0224] Step 6: Compound b-6 (139 g, 288 mmol) was dissolved in tetrahydrofuran (1390 mL), the reaction solution was cooled to 0°C, potassium tert-butoxide (48.5 g, 432 mmol) was added in batches, and the reaction was carried out at 0°C for 2 hours. LCMS showed that the reaction of the raw materials was complete, the reaction solution was poured into saturated ammonium chloride (1500 mL) for quenching, and the organic solvent was removed by concentration under reduced pressure, and ethyl acetate (800 mL×3) was used for extraction, the combined organic phases were washed with saturated brine (1500 mL), the organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and then silica gel column chromatography (PE:EA=10:1) was used to obtain a yellow oily product b-7 (65.7 g, Y:49%). LC-MS m / z(ESI):484.3 / 486.3[M+Na] + .
[0225] Step 7: Dissolve compound b-7 (72.0 g, 155.8 mmol) in toluene (1350 mL), add compound diboric acid pinacol ester (49.43 g, 171.4 mmol), [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (7.2 g, 10.9 mmol) and anhydrous potassium acetate (30.5 g, 311.6 mmol) in sequence under nitrogen protection, react at 100°C for 16 hours, LMCS shows that the raw materials react completely. Cool down to 25°C, filter the reaction solution with diatomaceous earth, wash the filter cake with ethyl acetate until the solution is colorless, concentrate the filtrate and chromatograph on a silica gel column (PE:EA=10:1) to obtain an off-white solid b-8 (64 g, Y:80%).
[0226] Step 8: Compound b-8 (64.0 g, 125.7 mmol) was dissolved in acetonitrile (320 mL) and tetrahydrofuran (640 mL). Under nitrogen protection, N-chlorosuccinimide (25.2 g, 188.6 mmol) was added at 0°C and reacted at 30°C for 16 hours. LCMS showed that the raw material was completely reacted. The temperature was lowered to 25°C, and the reaction solution was concentrated under reduced pressure to obtain a crude product (116 g). Isopropanol (348 mL) was added to the crude product, and the temperature was slowly lowered to 0°C. Water (348 mL) was added and stirred overnight, filtered, and the filter cake was washed with a small amount of isopropanol and water. The filter cake was collected and dried to obtain an off-white solid b-9 (63.5 g, Y: 92%). 1 H NMR (400MHz, CDCl3) δ7.46-7.39 (m, 2H), 7.32-7.20 (m, 5H), 6.69 (d, J = 9.6Hz, 1H), 4.52-3 .95(m,2H),3.57-3.22(m,2H),2.97-2.88(m,1H),2.02-1.80(m,2H),1.58-1.30(m,23H). LC-MS m / z(ESI):566.3[M+Na] + .
[0227] Step 9: Dissolve compound a-17 (30.0 g, 71.7 mmol) and compound b-9 (47.25 g, 86.85 mmol) in toluene (375 mL) and water (75 mL), and add tris(dibenzylideneacetone)dipalladium (6.45 g, 7.05 mmol), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (8.1 g, 14.1 mmol) and anhydrous potassium carbonate (30.0 g, 215.1 mmol) in sequence. React at 115 ° C for 16 hours under nitrogen protection. LCMS shows that the raw material is completely reacted. Cool to 25°C, filter the reaction solution with diatomaceous earth, wash with ethyl acetate (120 mL×2), extract and remove a small amount of water, combine the organic phases and wash with saturated brine (80 mL), dry the organic phase with anhydrous sodium sulfate, filter, concentrate the filtrate under reduced pressure, add acetonitrile (400 mL), stir overnight at 25°C, filter the solid, wash with acetonitrile (30 mL), purify the solid with silica gel column chromatography (THF:PE=1:5) to obtain white solid compound b (18.5 g, Y: 33%). LC-MS m / z(ESI):775.2[M+Na] + .
[0228] Example 3: Preparation of Intermediate c
[0229]
[0230] Step 1: Compound a-16 undergoes substitution reaction with iodomethane in the presence of potassium carbonate to synthesize compound c-1.
[0231] Step 2: Compound c-1 and compound b-9 can undergo Suzuki coupling reaction under the catalysis of tri(dibenzylideneacetone)dipalladium and 4,6-bis(diphenylphosphine)phenazine and with potassium phosphate as base to synthesize compound c-2.
[0232] Step 3: Compound c-2 undergoes hydrolysis reaction in the presence of lithium hydroxide to synthesize compound c.
[0233] Embodiment 4:
[0234] Method 1:
[0235]
[0236]
[0237] Step 1: Dissolve compound 51-1 (16.0 g, 69.9 mmol) in dimethyl carbonate (70 mL), cool the system to 0 ° C, and slowly add sodium hydride (8.3 g, 209.6 mmol, 60%) in batches. React at room temperature for 1 hour under nitrogen protection. LCMS shows that the raw material is completely reacted. Pour the reaction solution into ice water (300 mL), extract with ethyl acetate (400 mL × 3), combine the organic phases and wash with saturated brine (100 mL × 2), dry the organic phase with anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. Purify by silica gel column chromatography (EA: PE = 1: 5) to obtain a white solid compound 64-1 (11.3 g, Y: 56%). LC-MS m / z (ESI): 287.2 / 289.1 [M+H] + .
[0238] Step 2: Compound 64-1 (11.3 g, 39.4 mmol) was dissolved in N, N-dimethylformamide (100 mL), and iodomethane (11.2 g, 78.8 mmol) and anhydrous potassium carbonate (11.0, 79.7 mmol) were added in sequence. The mixture was reacted at 50 °C for 12 hours under nitrogen protection. LCMS showed that the raw material was completely reacted. The reaction solution was poured into ice water (300 mL), extracted with ethyl acetate (200 mL × 2), the combined organic phases were washed with saturated brine (80 mL × 2), the organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and purified by silica gel column chromatography (EA: PE = 1: 8) to obtain compound 64-2 (10.1 g, Y: 85%). LC-MS m / z (ESI): 301.1 / 303.1 [M+H] + .
[0239] Step 3: Dissolve compound 64-2 (5.8 g, 19.3 mmol) in methanol (44 mL), add sodium hydroxide aqueous solution (2.3 g, 57.5 mmol) dissolved in water (11 mL), and react at room temperature for 2 hours. LCMS shows that the raw material is completely reacted. The reaction solution is added to water (600 mL), extracted with ethyl acetate (150 mL × 2), the combined organic phases are washed with saturated brine (30 mL × 2), the organic phases are dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to obtain compound 64-3 (3.9 g, Y: 83%). LC-MS m / z (ESI): 243.1 / 245.0 [M+H] + .
[0240] Step 4: Dissolve compound 64-3 (3.9 g, 16.0 mmol) in tetrahydrofuran (35 mL), cool to 0°C, add sodium borohydride solid (1.2 g, 31.6 mmol) in batches, and react at room temperature for 3 hours. TLC shows that the raw material has reacted completely. Slowly add ice water (200 mL) to the reaction solution, extract with ethyl acetate (150 mL×2), wash the combined organic phases with saturated brine (40 mL), dry the organic phases with anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. Purify by silica gel column chromatography (EA:PE=1:10to EA:PE=1:1, Rf=0.5 and Rf=0.4) to obtain compounds 64-4a (1.1 g, Y:28%, Rf=0.5) and 64-4b (1.3 g, Y:33%, Rf=0.4). NOESY identified compound 64-4a as cis-configuration (such as Figure 1 ), 64-4b is the trans configuration (as shown Figure 2 64-4a: 1 H NMR (400MHz, CDCl3): δ7.17 (s, 1H), 7.06 (d, J = 8.4Hz, 1H), 5.15 (d, J = 6.0Hz, 1H) ,2.98-2.90(m,1H),2.78-2.70(m,1H),2.54-2.42(m,1H),1.20(d,J=6.8Hz,3H). 64-4b: 1 H NMR (400MHz, CDCl3): δ7.15 (s, 1H), 7.06 (d, J = 8.8Hz, 1H), 4.95 (d, J = 4.8Hz, 1H), 3.28-3.17 (m, 1H), 2.49-2.36 (m, 2H), 1.21-1.16 (m, 3H).
[0241] Step 5: Compound 64-4a (1.1 g, 4.5 mmol) was dissolved in anhydrous dichloromethane (15 mL), cooled to 0 ° C, imidazole (0.9 g, 13.2 mmol) and tert-butyldimethylsilyl chloride (1.0 g, 6.67 mmol) were added in sequence, and the mixture was reacted at room temperature under nitrogen protection for 5 hours. TLC showed that the raw material was completely reacted. Water (60 mL) was added to the reaction solution, extracted with ethyl acetate (80 mL × 2), the combined organic phases were washed with saturated brine (30 mL), the organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and purified by silica gel column chromatography (EA: PE = 1: 40) to obtain a colorless oil compound 64-5a (1.3 g, Y: 80%).
[0242] Step 6: Compound 64-5a (1.3 g, 3.6 mmol) was dissolved in N, N-dimethylformamide (10 mL), and zinc cyanide (260 mg, 2.2 mmol), tris(dibenzylideneacetone)dipalladium (330 mg, 0.36 mmol), and 1,1'-bis(diphenylphosphino)ferrocene (400 mg, 0.72 mmol) were added in sequence. The mixture was reacted at 100 °C for 16 hours under nitrogen protection. TLC showed that the raw material was completely reacted. After cooling to 25 °C, ice water (100 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (150 mL × 3). The organic phases were combined and washed with saturated brine (80 mL), and the organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by silica gel column chromatography (EA: PE = 1: 30) to obtain compound 64-6a (700 mg, Y: 63%). 1 H NMR (400MHz, CDCl3): δ7.29(s,1H),7.15(d,J=8.8,1H),5.17(d,J=5.2,1H),2.91-2.72 (m,2H),2.49-2.38(m,1H),1.13(d,J=6.8,3H),0.86(s,9H),0.15(s,3H),0.06(s,3H).
[0243] Step 7: Compound 64-6a (700 mg, 2.3 mmol) was dissolved in tetrahydrofuran (5 mL), cooled to -70 ° C, and under nitrogen protection, a solution of lithium diisopropylamide in tetrahydrofuran (1.3 mL, 2.6 mmol, 2 M) was added dropwise, and the mixture was reacted at -70 ° C for 1 hour. 1,2-dibromotetrafluoroethane (670 mg, 2.6 mmol) in tetrahydrofuran (1 mL) was added dropwise, and the mixture was reacted at -70 ° C for 1 hour. TLC showed that the reaction of the raw materials was complete. Saturated ammonium chloride solution (50 mL) was slowly added to the reaction solution, and ethyl acetate (50 mL × 3) was added for extraction. The combined organic phases were washed with saturated brine (15 mL), and the organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and purified by silica gel column chromatography (EA: PE = 1: 30) to obtain a light yellow solid compound 64-7a (640 mg, Y: 72%). 1 H NMR (400MHz, CDCl3): δ7.32 (s, 1H), 5.19 (d, J = 5.2, 1H), 2.90-2.69 (m, 2H), 2 .51-2.41(m,1H),1.12(d,J=6.8,3H),0.87(s,9H),0.16(s,3H),0.07(s,3H).
[0244] Step 8: Dissolve compound 64-7a (640 mg, 1.7 mmol) in ethanol (4 mL) and water (4 mL), add sodium hydroxide (660 mg, 16.5 mmol), and react at 100°C for 16 hours. TLC shows that the raw material reacts completely. The reaction solution is cooled to 0°C, water (20 mL) is added, and then dilute hydrochloric acid (0.5 M) is slowly added until the pH of the reaction system is 3-4. Extract with ethyl acetate (70 mL × 3), wash the combined organic phases with saturated brine (30 mL), dry the organic phase with anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure to obtain compound 64-8a (420 mg, crude).
[0245] Step 9: Compound 64-8a (420 mg, 1.5 mmol) was dissolved in N,N-dimethylformamide (5 mL), and diisopropylethylamine (760 mg, 5.9 mmol), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (600 mg, 1.6 mmol) and methylamine hydrochloride (180 mg, 2.7 mmol) were added in sequence, and the mixture was reacted at room temperature for 2 hours under nitrogen protection. LCMS showed that the raw materials were completely reacted. Water (30 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (30 mL×2). The organic phases were combined and washed with saturated brine (20 mL), and the organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and purified by silica gel column chromatography (EA:PE=1:5) to obtain compound 64-9a (380 mg, Y: 86%). LC-MS m / z(ESI):302.0 / 304.0[M+H] + .
[0246] Step 10: Dissolve compound 64-9a (380 mg, 1.7 mmol) in dichloromethane (6 mL), add imidazole (260 mg, 3.8 mmol) and tert-butyldimethylsilyl chloride (450 mg, 3.0 mmol) in turn. React at room temperature for 12 hours under nitrogen protection. TLC shows that the raw material is completely reacted. The reaction solution is concentrated under reduced pressure and purified by silica gel column chromatography (EA: PE = 1: 10) to obtain compound 64-10a (400 mg, Y: 76%). 1 H NMR (400MHz, CDCl3): δ7.15(s,1H),5.93(br,1H),5.16(d,J=5.2,1H),3.01(d,J=5.2,3H),2.84-2.78(m ,1H),2.76-2.66(m,1H),2.45-2.38(m,1H),1.11(d,J=6.8,3H),0.86(s,9H),0.15(s,3H),0.07(s,3H).
[0247] Step 11: Compound 64-10a (270 mg, 0.65 mmol) and compound b-9 (353 mg, 0.65 mmol) were dissolved in toluene (6 mL) and water (1.2 mL), and tris(dibenzylideneacetone)dipalladium (60 mg, 0.07 mmol), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (75 mg, 0.13 mmol) and anhydrous potassium carbonate (270 mg, 1.96 mmol) were added in sequence. The mixture was reacted at 110°C overnight under nitrogen protection. LCMS showed that the raw material was completely reacted. The mixture was cooled to 25°C, the reaction solution was concentrated under reduced pressure, and then purified by silica gel column chromatography (EA:PE=1:5to1:1, Rf=0.6 and Rf=0.5, where Rf=0.5 is the target product) to obtain compound 64-11a (100 mg, Y: 20%). LC-MS (1.5ml-3.2min-5-95%B): Rt=2.450, m / z (ESI): 753.4 / 755.5[M+H] + .
[0248] Step 12: Compound 64-11a (100 mg, 0.13 mmol) was dissolved in hydrochloric acid / dioxane solution (2 mL, 4.0 M) and reacted at 25°C for 0.5 h. LCMS showed that the reaction of the raw material was complete. The reaction solution was concentrated under reduced pressure and purified by preparative high performance liquid chromatography (column model: Xselect CSH Prep Fluoro-Phenyl, 150*19 mm, 5 um; eluent 0.1% FA-CAN; gradient: 20-65 MeCN in H2O; flow rate: 20 ml / min: running time 12 min; elution time Rt = 8.0 min / 9.0 min) to obtain compound 64a1 (41.7 mg, Y: 58%, Rt = 9.0 min, formate) and 64a2 (9.9 mg, Y: 14%, Rt = 8.0 min, formate).
[0249] 64a1: 1 H NMR (400MHz, DMSO-d6): δ8.22-8.17(br,2H),7.44-7.25(m,6H),7.02(d,J=9.6Hz,1H),4.96(d,J=6.0Hz,1H),3.66-3.59(m,1 H),3.49-3.44(m,2H),2.99-2.67(m,4H),2.62(d,J=4.8Hz,3H),2.44-2.37(m,1H),1.68-1.41(m,4H),1.10(d,J=6.8Hz,3H). LC-MS m / z(ESI):539.2 / 541.2[M+H] +Chiral analysis (column model: Celluiose-SB, 100*4.6 mm, 5 um; eluent Hexane (0.1% DEA)-IPA; gradient: isocratic 9 / 1, flow rate: 1 ml / min: running time 10.0 min; peak time 5.75 min).
[0250] 64a2: 1 H NMR (400MHz, DMSO-d6): δ8.24(br,1H),8.14-8.11(br,1H),7.43-7.24(m,6H),7.00(d,J=9.6Hz,1H),5.15(br,1H),4.96(d,J=5.6Hz,1H),3 .53-3.49(m,1H),3.43-3.38(m,2H),2.98-2.64(m,4H),2.62(d,J=4.4Hz,3H),2.43-2.37(m,1H),1.59-1.35(m,4H),1.10(d,J=6.8Hz,3H). LC-MS m / z(ESI):539.3 / 541.3[M+H] + Chiral analysis (column model: Celluiose-SB, 100*4.6 mm, 5 um; eluent Hexane (0.1% DEA)-IPA; gradient: isocratic 9 / 1, flow rate: 1 ml / min: running time 8.0 min; peak time 4.76 min).
[0251] Method 2
[0252] The chiral synthesis method of 64a1, the synthesis of intermediate b is detailed in Example 2, and intermediate b is deprotected to obtain 64a1.
[0253]
[0254] Step 1: Dissolve compound intermediate b (6.09 g, 8.09 mmol) in hydrochloric acid / dioxane solution (31.5 mL, 4.0 M) and react at 25°C for 1 hour. LCMS showed that the raw material reacted completely. The reaction solution was concentrated under reduced pressure to obtain a yellow solid compound, which was purified by preparative high performance liquid chromatography (column model: YMC Triart Prep C18-S, 250*50 mm, 10 um; eluent 0.05% NH3H2O-10MMOL / L NH4HCO3-ACN; gradient: 48-68 MeCN in H2O; flow rate: 120 ml / min: running time 18 min; peak time Rt = 12.5 min) to obtain a white solid compound 64a1 (3.50 g, Y: 80%, free amine). 1H NMR (400MHz, DMSO-d6): δ8.16(q,J=4.4Hz,1H),7.45-7.39(m,2H),7.37-7.31(m,2H),7.30- 7.24(m,2H),7.00(d,J=9.6Hz,1H),5.14(d,J=6.4Hz,1H),4.96(t,J=6.0Hz,1H),3.58-3.50( m,1H),3.50-3.42(m,1H),3.00-2.92(m,1H),2.90-2.82(m,1H),2.76-2.70(m,2H),2.68-2.6 4(m,1H),2.62(d,J=4.4Hz,3H),2.45-2.37(m,1H),1.63-1.35(m,4H),1.11(d,J=6.8Hz,3H). LC-MS m / z(ESI):539.2 / 541.3[M+H] + .
[0255] High performance liquid analysis (column model: Halo 90A C18, 4.6*100mm, 2.7um; eluent 5-95% acetonitrile-0.1% H3PO4 in water; flow rate: 1.2ml / min: running time 13.0min; compound 64a1 elution time 5.269min, isomer compound 64a2 elution time 4.789min). Chiral analysis (column model: Celluiose-SB, 100*4.6mm, 3um; eluent Hexane (0.1% DEA)-IPA; gradient: isocratic 9 / 1, flow rate: 1ml / min: running time 10.0min; elution time 5.38min, isomer compound 64a2 elution time 4.61min).
[0256] When performing HPLC and chiral analysis, the product prepared by method 2 was mixed with compound 64a1 and compound 64a2 prepared by method 1 for analysis. The results of mixing with compound 64a1 prepared by method 1 showed a single peak. Combined with NMR, it can be inferred that the configuration of product 64a1 prepared by method 2 is consistent with that of product 64a1 prepared by method 1. The results of mixing with compound 64a2 prepared by method 1 showed two peaks, of which the first peak was the isomer compound 64a2.
[0257] Example 5
[0258]
[0259]
[0260] Step 1: Dissolve compound 64-7a (300 mg, 0.78 mmol) and compound b-9 (382 mg, 0.70 mmol) in toluene (6 mL) and water (1.2 mL), and add tris(dibenzylideneacetone)dipalladium (107 mg, 0.11 mmol), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (135 mg, 0.23 mmol) and anhydrous potassium carbonate (323 mg, 2.34 mmol) in sequence. React at 110°C overnight under nitrogen protection. LCMS shows that the raw material reacts completely. Cool to 25°C, concentrate the reaction solution under reduced pressure, and purify it by silica gel column chromatography (EA:PE=1:8) to obtain compound 82-1 (390 mg, Y: 69%). LC-MS m / z (ESI): 665.3 [M-tBu+H] + .
[0261] Step 2: Compound 82-1 (390 mg, 0.54 mmol) and anhydrous potassium carbonate (250 mg, 1.81 mmol) were dissolved in dimethyl sulfoxide (7 mL), cooled to 10 ° C, and hydrogen peroxide (190 mg, 30%) was slowly added dropwise. The reaction was allowed to react at room temperature for 1 hour. LCMS showed that the raw material was completely reacted. The reaction solution was poured into water (50 mL), extracted with ethyl acetate (50 mL × 2), and the combined organic phases were washed with saturated brine (10 mL). The organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Purification by silica gel column chromatography (EA: PE = 1: 20 to 1: 5, Rf = 0.6, Rf = 0.5, where Rf = 0.5 is the target product) gave compound 82-2a (150 mg, Y: 37%). LC-MS m / z (1.5ml-5min-5-95%B): Rt=3.910 / 3.957, (ESI): 739.3[M+H] + .
[0262] Step 3: Compound 82-2a (150 mg, 0.20 mmol) was dissolved in hydrochloric acid / dioxane solution (4 mL, 4.0 M) and reacted at 25°C for 0.5 h. LCMS showed that the reaction of the raw material was complete. The reaction solution was concentrated under reduced pressure and purified by preparative high performance liquid chromatography (column model: Xselect CSH Prep Fluoro-Phenyl, 150*19 mm, 5 um; eluent 0.1% FA-ACN; gradient: 20-55% ACN in H2O; flow rate: 20 ml / min: running time 12 min; elution time Rt = 7.8 min / 8.9 min) to obtain compounds 82a1 (53.0 mg, FA salt, Y: 45%, Rt = 7.8 min) and 82a2 (46.9 mg, FA salt, Y: 40%, Rt = 8.9 min).
[0263] 82a1: 1 H NMR (400MHz, DMSO-d6): δ8.26-8.19(br,1H),7.66(br,1H),7.49-7.40(m,2H),7.38-7.24(m,5H),7.02(d,J=9.6Hz,1H),4.96(d,J =6.4Hz,1H),3.69-3.56(m,1H),3.52-3.43(m,1H),3.00-2.61(m,5H),2.43-2.36(m,1H),1.71-1.31(m,4H),1.11(d,J=7.2Hz,3H). LC-MS m / z(ESI):525.2 / 527.2[M+H] + Chiral analysis (column model: Amylose-SA, 100*4.6 mm, 3 um; eluent Hexane (0.1% DEA)-IPA; gradient: isocratic 9 / 1, flow rate: 1 ml / min: running time 8.5 min; peak time 4.91 min).
[0264] 82a2: 1 H NMR (400MHz, DMSO-d6): δ8.22(br,1H),7.67(br,1H),7.46-7.22(m,7H),7.02(d,J=9.6Hz,1H),4.96(d,J=6.0Hz,1H),3. 67-3.59(m,1H),3.54(d,J=16.0Hz,1H),3.00-2.61(m,5H),2.45-2.37(m,1H),1.76-1.31(m,4H),1.11(d,J=6.8Hz,3H). LC-MS m / z(ESI):525.2 / 527.3[M+H] + Chiral analysis (column model: Amylose-SA, 100*4.6 mm, 3 um; eluent Hexane (0.1% DEA)-IPA; gradient: isocratic 9 / 1, flow rate: 1 ml / min: running time 8.5 min; peak time 5.05 min).
[0265] Embodiment 6:
[0266] Method 1
[0267]
[0268] Step 1: Dissolve compound 64-10a (300 mg, 0.72 mmol) and compound a-9 (466 mg, 1.15 mmol) in toluene (5 mL) and water (1 mL), and add tris(dibenzylideneacetone)dipalladium (99 mg, 0.11 mmol), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (125 mg, 0.22 mmol) and anhydrous potassium carbonate (298 mg, 2.16 mmol) in sequence. React at 110°C overnight under nitrogen protection. LCMS shows that the raw material reacts completely. Cool to 25°C, concentrate the reaction solution under reduced pressure, and then chromatograph on a silica gel column (EA:PE=1:10 to 1:1, Rf=0.6 and Rf=0.5, where Rf=0.5 is the target product) to obtain a crude product. The crude product was purified by C18 silica gel column (C18, 40.0 g, gradient: 70-90% MeCN in H2O; flow rate: 30 ml / min: running time 10 min) to give compound 90-1 (160 mg, Y: 36%). LC-MS (1.5 ml-3.2 min-5-95% B): Rt=1.847, m / z (ESI)): 614.3 / 616.3 [M+H] + .
[0269] Step 2: Dissolve compound 90-1 (160 mg, 0.26 mmol) in anhydrous dichloromethane (4 mL), add Dess-Martin periodinant (165 mg, 0.39 mmol) and solid sodium bicarbonate (60 mg, 0.71 mmol) in turn, and react at 25 ° C for 0.5 hours under nitrogen protection. LCMS shows that the raw material is completely reacted. Add saturated sodium thiosulfate aqueous solution (20 mL) to the reaction solution, extract with ethyl acetate (15 mL×2), combine the organic phases and wash with saturated brine (10 mL×2), dry the organic phase with anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure to obtain crude compound 90-2 (120 mg, crude). LC-MS m / z (ESI): 612.2 [M+H] + .
[0270] Step 3: Compound 90-2 (120 mg, 0.20 mmol) was dissolved in dichloroethane (4 mL), trans-4-amino-1-methylcyclohexanol (46 mg, 0.35 mmol) and acetic acid (15 mg, 0.25 mmol) were added, and the mixture was reacted at 80°C for 2 hours. After cooling to 25°C, sodium triacetyl borohydride (127 mg, 0.60 mmol) was added, and the mixture was reacted at 60°C for 0.5 hours. LCMS showed that the reaction of the raw materials was complete. After cooling to 25°C, water (20 mL) was added to the reaction solution, and the mixture was extracted with dichloromethane (30 mL×2). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified on a silica gel plate (EA:PE=1:4) to obtain compound 90-3 (60 mg, Y: 42%). LC-MS m / z(ESI)):725.4 / 727.4[M+H] + .
[0271] Step 4: Compound 90-3 (60 mg, 0.08 mmol) was dissolved in hydrochloric acid / dioxane solution (2 mL, 4.0 M) and reacted at 25°C for 0.5 hours. LCMS showed that the raw material was completely reacted. The reaction solution was concentrated under reduced pressure and then purified by preparative high performance liquid chromatography (column model: YMC-Actus Triart C18, 150*20 mm, 5 um; elution: 0.1% FA-CAN; gradient: 20-50% MeCN in H2O; flow rate: 20 ml / min: running time 11 min; elution time 8.5 min / 9.3 min) to obtain compound 90a1 (4.5 mg, Y: 8.3%, formate, elution time 8.5 min) and compound 90a2 (16.6 mg, Y: 30%, formate, elution time 9.3 min).
[0272] 90a1: 1 H NMR (400MHz, DMSO-d6): δ8.25-8.19(br,1H),7.40-7.24(m,6H),7.02(d,J=10.0Hz,1H),5.20-5.11(br,1H),4.97-4.90(m,1H),4.09-4.10( br,1H),3.45-3.38(m,1H),2.98-2.69(m,5H),2.63(d,J=4.4Hz,3H),2.43-2.34(m,1H),1.70-1.14(m,6H),1.13-1.02(m,5H),1.00(s,3H). LC-MS m / z(ESI):611.4 / 613.4[M+H] +Chiral analysis (column model: Celluiose-C, 100*4.6 mm, 3 μm; eluent Hexane (0.1% DEA)-IPA; gradient: isocratic 4 / 1, flow rate: 1 ml / min: running time 8.0 min; peak time 3.26 min).
[0273] 90a2: 1 H NMR (400MHz, DMSO-d6): δ8.27-8.11(br,1H),8.17(br,1H),7.40-7.25(m,6H),7.03(d,J=9.6Hz,1H),5.22-5.00(br,1H),4.95(d,J=6.0Hz,1H),4.1 5-3.90(br,1H),3.50-3.43(m,1H),3.00-2.65(m,5H),2.63(d,J=4.4Hz,3 H),2.44-2.34(m,1H),1.70-1.16(m,6H),1.14-1.03(m,5H),1.01(s,3H). LC-MS m / z(ESI):611.4 / 613.4[M+H] + Chiral analysis (column model: Celluiose-C, 100*4.6 mm, 3 μm; eluent Hexane (0.1% DEA)-IPA; gradient: isocratic 4 / 1, flow rate: 1 ml / min: running time 8.0 min; peak time 2.90 min).
[0274] Example 7
[0275]
[0276] Step 1: Dissolve 4-amino-3-methylphenol (10.0 g, 81.20 mmol) in toluene (100 mL), add acrylic acid (17.5 g, 243.6 mmol), stir at 100°C for 2 hours, TLC (EA:PE=2:1) shows that the raw material is reacted completely, and the reaction solution is concentrated under reduced pressure to obtain a yellow solid compound 1-1 (20 g, crude).
[0277] Step 2: Compound 1-1 (20 g, 74.83 mmol) was dissolved in toluene (100 mL) and acetic acid (100 mL), urea (4.5 g, 74.83 mmol) was added, and the mixture was reacted at 120°C for 12 hours. TLC (EA:PE=2:1) showed that the reaction of the raw materials was complete. The reaction solution was adjusted to pH=8 by adding saturated sodium bicarbonate, extracted with dichloromethane (500 mL×3), the combined organic phases were washed with saturated brine (100 mL×3), the organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain yellow solid compound 1-2 (10 g, crude). 1 H NMR (400MHz, DMSO-d6) δ10.17(br,1H),7.02-6.97(m,1H),6.64-6.58(m,2H),3.68-3.63(m,1H),3.47-3.41(m,1H),2.76-2.62(m,2H),2.07(s,3H). LC-MS m / z(ESI):221.0[M+H] + .
[0278] Step 3: Dissolve compound 1-2 (2.5 g, 11.35 mmol) in acetonitrile (50 mL), add ethyl bromoacetate (2.84 g, 17.03 mmol) and potassium carbonate (3.14 g, 22.70 mmol), react at 80 ° C for 16 hours, LCMS shows that the raw material is completely reacted. Dilute the reaction solution with water, extract with ethyl acetate (100 mL × 3), combine the organic phases and wash with saturated brine (20 mL × 3), dry the organic phase with anhydrous sodium sulfate, concentrate under reduced pressure, and purify by silica gel column chromatography (THF: PE = 2: 1) to obtain yellow solid compound 1-3 (1.5 g, 43%). LC-MS m / z (ESI): 307.1 [M + H] + .
[0279] Step 4: Dissolve compound 1-3 (600 mg, 1.96 mmol) in tetrahydrofuran (9 mL) and water (3 mL), add lithium hydroxide (94 mg, 3.92 mmol), react at 0°C for 2 hours, LCMS shows that the raw material is completely reacted. Add dilute hydrochloric acid (2M) to adjust the pH to 4-5, extract with ethyl acetate (20 mL×3), combine the organic phases, and concentrate under reduced pressure to obtain a light yellow solid compound 1-4 (500 mg, 91%). LC-MS m / z (ESI): 279.0 [M+H] + .
[0280] Step 5: Compound 1-4 (400 mg, 1.41 mmol) and tert-butyl 4-(piperidin-4-methylene)-piperidin-1-carboxylate (406 mg, 1.41 mmol) were dissolved in N,N-dimethylformamide (4 mL), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (819 mg, 2.16 mmol) and N,N-diisopropylethylamine (557 mg, 4.31 mmol) were added, and the reaction was carried out at room temperature for 2 hours. LCMS showed that the raw materials were completely reacted. The reaction solution was diluted with water, extracted with ethyl acetate (50 mL × 3), the combined organic phases were washed with saturated brine (20 mL × 3), the organic phases were dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by C18 reverse phase (ACN:H2O = 70%) to obtain a light yellow solid compound 1-5 (450 mg, 57%). LC-MS m / z(ESI):565.3[M+Na] + .
[0281] Step 6: Dissolve compound 1-5 (150 mg, 0.28 mmol) in acetonitrile (3 mL), add trimethylsilyl iodide (77 mg, 0.55 mmol), and react at room temperature for 2 hours. LCMS shows that the raw material is completely reacted. The reaction solution is concentrated under reduced pressure to obtain white solid compound 1-6 (120 mg, crude). LC-MS m / z (ESI): 443.0 [M+H] + .
[0282] Step 7: Compound a (120 mg, 0.16 mmol) and 1-6 (79 mg, 0.18 mmol) were dissolved in N,N-dimethylformamide (2 mL), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (93 mg, 0.24 mmol) and N,N-diisopropylethylamine (63 mg, 0.49 mmol) were added, and the reaction was carried out at room temperature for 2 hours. LCMS showed that the raw materials were completely reacted. The reaction solution was purified by C18 reverse phase (ACN:H2O=32%) to obtain a light yellow solid compound 1-7 (130 mg, 68%). LC-MS m / z (ESI): 1164.4 [M+H] + .
[0283] Step 8: Compound 1-7 (100 mg, 0.86 mmol) was dissolved in methanol (1 mL), and a methanol solution of hydrochloric acid (1 mL, 4 M) was added, and the mixture was reacted at 25°C for 1 hour. LCMS showed that the reaction of the raw material was complete. The reaction solution was concentrated under reduced pressure by adding dimethyl sulfoxide (1 mL), and then purified by high-efficiency preparative liquid phase (column model: YMC-Actus Triart C18, 150*20 mm, 5 um; eluent: 0.05% NH3H2O-10mmoL / L NH4HCO3-ACN=1:1; gradient: 37%-57%; flow rate: 20 mL / min; running time: 10 min; peak time: 9.0 min) to obtain a white solid compound 1 (59.2 mg, Y: 65%). 1 H NMR(400MHz,DMSO-d6)δ10.27(s,1H),8.23(d,J=4.4Hz,1H),7.39-7.25(m,6H),7.17-7.12(m,1 H),7.06-7.01(m,1H),6.82-6.74(m,2H),5.18-5.13(m,1H),4.97-4.92(m,1H),4.80-4.72(m,2 H),4.36-4.28(m,2H),3.86-3.66(m,3H),3.51-3.44(m,2H),2.93-2.79(m,5H),2.58-2.51(m,7 H),2.44-2.39(m,3H),2.14-2.09(m,1H),2.13(s,3H),1.83-1.56(m,10H),1.30-0.79(m,14H). LC-MS m / z(ESI):1049.6[M+H] + .
[0284] Example 8
[0285]
[0286]
[0287] Step 1: Compound 2-1 can undergo a condensation reaction with compound 2-2 in the presence of a condensation agent, 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, to synthesize compound 2-3.
[0288] Step 2: Compound 2-3 undergoes a de-tert-butyloxycarbonyl reaction in the presence of trifluoroacetic acid to synthesize compound 2-4.
[0289] Step 3: Compound 2-4 can undergo a condensation reaction with tert-butyloxycarbonyl 6-aminocaproic acid in the presence of a condensation agent, 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, to synthesize compound 2-5.
[0290] Step 4: Compound 2-5 undergoes a de-tert-butyloxycarbonyl reaction in the presence of trifluoroacetic acid to synthesize compound 2-6.
[0291] Step 5: Compound 2-6 can undergo a condensation reaction with compound c in the presence of a condensation agent, 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, to synthesize compound 2-7.
[0292] Step 6: Compound 2-7 undergoes de-tert-butyloxycarbonyl and de-tert-butyldimethylsilyl reactions in the presence of dioxane hydrochloride to synthesize compound 2.
[0293] Example 9
[0294]
[0295] Method 1:
[0296] Step 1: Compound 3-1 can undergo a condensation reaction with adipic acid in the presence of a condensation agent, 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, to synthesize compound 3-2.
[0297] Step 2: Compound a-19 and ammonium acetate undergo a reductive amination reaction in the presence of sodium cyanoborohydride to synthesize compound 3-3.
[0298] Step 3: Compound 3-3 can undergo a condensation reaction with compound 3-2 in the presence of a condensation agent, 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, to synthesize compound 3-4.
[0299] Step 4: Compound 3-4 is subjected to a de-tert-butyldimethylsilylation reaction in the presence of dioxane hydrochloride to synthesize compound 3.
[0300] Method 2:
[0301] Step 1: Compound a-19 (290 mg, 0.49 mmol) was dissolved in 1,2-dichloroethane (3.0 mL). Under nitrogen protection, ammonia methanol solution (0.7 ml, 7 M) and acetic acid (2.94 mg, 0.0049 mmol) were added in sequence. The temperature was raised to 80 ° C and stirred for 2 hours. Sodium acetate borohydride (154 mg, 2.45 mmol) was added and stirred at 80 ° C for 30 minutes. LCMS showed that the raw material reaction was complete. The temperature was lowered to 25 ° C, and the reaction solution was poured into saturated sodium bicarbonate (20 mL) for quenching. The mixture was extracted with ethyl acetate (20 mL × 3), and the organic phases were combined and washed with saturated brine (20 mL). The organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography (EA: PE = 1: 10 to 1: 2) to obtain a white solid compound 3-3 (134 mg, Y: 45%). LC-MS m / z(ESI):612.2[MH] - .
[0302] Step 2: Compound 3-1 (1 g, 3.66 mmol) was dissolved in dimethyl sulfoxide (10 mL), cooled to 0 ° C, and adipic acid (1.59 g, 9.15 mmol), N, N, N', N'-tetramethylchloroformamidine hexafluorophosphate (4.11 g, 14.6 mmol) and N-methylimidazole (3.31 g, 40.2 mmol) were added in sequence, and the mixture was reacted at room temperature for 4 hours under nitrogen protection. TLC (DCM: MeOH = 10: 1) showed that the raw materials were completely reacted. The reaction solution was added with saturated sodium bicarbonate aqueous solution (50 mL), extracted with dichloromethane (50 mL × 3), the combined organic phases were washed with saturated brine (50 mL × 2), the organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by silica gel column chromatography (EA: PE = 1: 10 to 1: 1) to obtain white solid compound 3-2 (220 mg, Y: 23%). 1 H NMR (400MHz, DMSO-d6) δ11.10(s,1H),10.63(s,1H),8.25(d,J=1.4Hz,1H),7.93-7.80(m,2H),5.11(dd,J=12.9,5.5Hz,1H) ,2.93-2.84(m,2H),2.67-2.54(m,1H),2.40(t,J=7.1Hz,2H),2.23(d,J=7.1Hz,2H),2.09-2.03(m,1H),1.67-1.51(m,4H).
[0303] Step 3: Compound 3-3 (100 mg, 0.16 mmol) was dissolved in N, N-dimethylformamide (2.0 mL), cooled to 0 ° C, 3-2 (80.0 mg, 0.14 mmol), N, N, N', N'-tetramethylchloroformamidine hexafluorophosphate (140 mg, 0.85 mmol) and N-methylimidazole (340 mg, 4.09 mmol) were added in sequence, and the mixture was reacted at room temperature for 16 hours under nitrogen protection. TLC (DCM: MeOH = 10: 1) showed that the raw materials reacted completely. The reaction solution was added with saturated sodium bicarbonate aqueous solution (50 mL), extracted with dichloromethane (50 mL × 3), the combined organic phases were washed with saturated brine (50 mL × 2), the organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by silica gel column chromatography (EA: PE = 1: 10 to 1: 1) to obtain white solid compound 3-4 (80 mg, Y: 49%). LC-MS m / z(ESI):996.6[M+H] + .
[0304] Step 4: Compound 3-4 (70 mg, 0.070 mmol) was dissolved in a methanol solution of hydrochloric acid (1 mL, 4.0 M) and reacted at room temperature for 30 minutes. LCMS showed that the raw material was completely reacted. The reaction solution was concentrated under reduced pressure to a yellow solid compound (50 mg, crude), and purified by high-efficiency preparative liquid phase (column model: YMC-Actus Triart C18, 150*20 mm, 5 um; eluent: 0.05% NH3H2O-10 MMOL / L NH4HCO3-ACN; gradient: 34-54 MeCN in H2O; flow rate: 20 ml / min: running time 18 min; peak time Rt = 12 min) to obtain a white solid compound 3 (15 mg, Y: 24%). 1H NMR(400MHz,DMSO-d6)δ11.09(s,1H),10.50(s,1H),8.35-8.25(m,2H),7.92-7.79(m,3H),7.40-7.25(m ,6H),7.00(d,J=9.6Hz,1H),5.18-5.06(m,2H),4.95(t,J=6.0Hz,1H),3.69(q,J=7.1Hz,1H),3.57-3.48( m,1H),3.48-3.38(m,1H),3.29-3.20(m,2H),2.98-2.84(m,3H),2.76-2.66(m,1H),2.64(d,J=4.4Hz,3H ),2.44-2.37(m,1H),2.31(t,J=7.0Hz,2H),2.11-1.99(m,3H),1.48-1.24(m,5H),1.10(d,J=6.9Hz,3H). LC-MS m / z(ESI):882.3[M+H] + .
[0305] Example 10
[0306]
[0307]
[0308] Step 1: Compound 4-1 (274 mg, 0.1 mmol) was dissolved in acetonitrile (3 mL), potassium carbonate (193 mg, 1.5 mmol) and tert-butyl bromoacetate (292 mg, 1.5 mmol) were added in sequence, and the mixture was reacted at 80 °C for 16 hours under nitrogen protection. TLC (PE: EA = 3: 1) showed that the raw materials were completely reacted. The reaction solution was added with saturated aqueous ammonium chloride solution (50 mL), extracted with dichloromethane (50 mL × 3), the combined organic phases were washed with saturated brine (50 mL × 2), the organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by silica gel column chromatography (EA: PE = 1: 10 to 1: 1) to obtain white solid compound 4-2 (300 mg, Y: 77%).
[0309] Step 2: Dissolve compound 4-2 (300 mg, 0.77 mmol) in dichloromethane (2.5 mL), add trifluoroacetic acid (0.5 mL), and react at 25 ° C for 2 hours under nitrogen protection. TLC (PE: EA = 1: 1) shows that the raw material is completely reacted. Add saturated sodium bicarbonate aqueous solution (20 mL) to the reaction solution, extract with dichloromethane (20 mL × 3), combine the organic phases and wash with saturated brine (20 mL × 2), dry the organic phase with anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure to obtain a white solid compound 4-3 (200 mg, Y: 78%).
[0310] Step 3: Compound 4-3 (200 mg, 0.61 mmol) was dissolved in dichloromethane (2 mL), cooled to 0°C, 4-(piperidin-4-methylene)-piperidin-1-carboxylic acid tert-butyl ester (255 mg, 0.91 mmol), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (274 mg, 0.72 mmol) and N,N-diisopropylethylamine (156 mg, 1.2 mmol) were added in sequence, and reacted at 25°C for 2 hours under nitrogen protection. LCMS showed that the raw material was completely reacted. The reaction solution was added with saturated sodium bicarbonate aqueous solution (50 mL), extracted with dichloromethane (50 mL × 3), the combined organic phases were washed with saturated brine (50 mL × 2), the organic phases were dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and purified by silica gel column chromatography (PE: EA = 1: 1) to obtain white solid compound 4-4 (120 mg, Y: 33%). LC-MS m / z (ESI): 619.4 [M + Na] + .
[0311] Step 4: Dissolve compound 4-4 (120 mg, 0.21 mmol) in dichloromethane (2.5 mL), add trifluoroacetic acid (0.5 mL), and react at 25 ° C for 2 hours under nitrogen protection. LCSM shows that the raw material is completely reacted. Add saturated sodium bicarbonate aqueous solution (20 mL) to the reaction solution, extract with dichloromethane (20 mL × 3), combine the organic phases and wash with saturated brine (20 mL × 2), dry the organic phase with anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure to obtain a white solid compound 4-5 (99 mg, Y: 99%). LC-MS m / z (ESI): 497.1 [M+H] + .
[0312] Step 5: Compound a (100 mg, 0.13 mmol) and 4-5 (80 mg, 0.16 mmol) were dissolved in dichloromethane (4 mL), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (102 mg, 0.27 mmol) and N,N-diisopropylethylamine (69.9 mg, 0.54 mmol) were added, and the mixture was reacted at 25°C for 2 hours. TLC showed that the reaction of the raw materials was complete. The reaction solution was diluted with water, extracted with ethyl acetate (50 mL × 3), the combined organic phases were washed with saturated brine (20 mL × 3), the organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a light yellow solid compound 4-6 (70 mg, 48%).
[0313] Step 6: Compound 4-6 (70 mg, 0.64 mmol) was dissolved in dichloromethane (1 mL), and a hydrochloric acid dioxane solution (1 mL, 4 M / L) was added, and the mixture was reacted at 25°C for 2 hours. LCMS showed that the reaction of the raw material was complete. After the reaction solution was concentrated under reduced pressure, it was purified by high-efficiency preparative liquid phase (column model: Xselect CSH Prep Fluoro-Phenyl, 150*19 mm, 5 um; eluent: 0.1% FA-ACN; gradient: 30%-50%; flow rate: 20 mL / min; running time: 9 min; peak elution time: 8.5 min) to obtain a white solid compound 4 (20.0 mg, Y: 27%). 1 H NMR (400MHz, DMSO-d6) δ11.10(s,1H),8.25(s,1H),7.83(d,J=8.2Hz,1H),7.40-7.37(m,5H),7.35-7.30(m ,3H),7.06(d,J=9.3Hz,1H),5.14-5.05(m,4H),4.95(t,J=6.0Hz,1H),4.39-4.25(m,2H),3.86-3.76(m,2H) ,3.53-3.43(m,1H),3.12-2.67(m,8H),2.64(d,J=4.4Hz,3H),2.62-2.54(m,3H),2.44-2.33(m,3H),2.10-1 .99(m,2H),1.89-1.75(m,2H),1.71-1.50(m,8H),1.32-1.20(m,4H),1.14-1.09(m,6H),1.00-0.77(m,4H). LC-MS m / z(ESI):1103.5[M+H] + .
[0314] Embodiment 11
[0315]
[0316] Step 1: Dissolve the compound (3-amino-4-methylphenyl)-tert-butyl carbamate (2.5 g, 11.2 mmol) in toluene (25 mL), add ethyl 3-bromopropionate (3.0 g, 16.9 mmol) and potassium carbonate (1.6 g, 11.2 mmol), and react at 80°C for 48 hours. LCMS shows that the raw material is completely reacted. Extract with ethyl acetate (30 mL × 3), wash the combined organic phase with saturated brine (30 mL × 3), dry the organic phase with anhydrous sodium sulfate, filter, concentrate the filtrate under reduced pressure, and purify it by silica gel column chromatography (THF: PE = 1: 9) to obtain a white solid compound 5-1 (2.3 g, Y: 63%). LC-MS m / z (ESI): 323.2 [M + H]+ . 1 H NMR (400MHz, DMSO-d6): δ8.94(s,1H),6.80(d,J=8.0Hz,1H),6.72(s,1H),6.65(d,J=7.6Hz,1H),4.80-4.70( m,1H),4.15-4.00(m,2H),3.30-3.25(m,2H),2.66-2.55(m,2H),1.97(s,3H),1.45(s,9H),1.22-1.17(m,3H).
[0317] Step 2: Dissolve compound 5-1 (2.0 g, 6.2 mmol) in acetic acid (20 mL), add potassium cyanate (528 mg, 6.2 mmol), and react at 25°C for 16 hours. LCMS showed that the raw material was completely reacted. The reaction solution was concentrated under reduced pressure to obtain a crude brown solid compound 5-2 (1.5 g, crude). LC-MS m / z (ESI): 366.2 [M+H] + .
[0318] Step 3: Dissolve compound 5-2 (1.5 g, 4.1 mmol) in concentrated hydrochloric acid (15 mL) and react at 25°C for 16 hours. LCMS showed that the raw material reacted completely. The reaction solution was concentrated under reduced pressure, acetonitrile (15 mL) was added and stirred for 2 hours, and filtered to obtain a white solid compound 5-3 (0.9 g, Y: 99%). LC-MS m / z (ESI): 220.1 [M+H] + .
[0319] Step 4: Compound 5-3 (300 mg, 1.4 mmol) and 5-(tert-butoxyformyl)valeric acid (250 mg, 1.2 mmol) were dissolved in dry N,N-dimethylformamide (3 mL), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (656 mg, 1.7 mmol) and triethylamine (582 mg, 5.7 mmol) were added, and the mixture was reacted at 25°C for 2 hours. LCMS showed that the raw materials were completely reacted. The reaction solution was added with water (15 mL), extracted with ethyl acetate (15 mL×3), the combined organic phases were washed with saturated brine (15 mL×3), the organic phases were dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and purified by silica gel column chromatography (THF:PE=3:2) to obtain white solid compound 5-4 (130 mg, Y: 27%). LC-MS m / z(ESI):441.3[M+Na] + .
[0320] Step 5: Compound 5-4 (120 mg, 0.28 mmol) was dissolved in dichloromethane (3 mL), trifluoroacetic acid (1 mL) was added dropwise at 0°C, and the mixture was reacted at 25°C for 2 hours. LCMS showed that the reaction of the raw material was complete. The reaction solution was concentrated under reduced pressure to obtain brown solid compound 5-5 (90 mg, crude). LC-MS m / z (ESI): 319.2 [M+H] + .
[0321] Step 6: Compound 5-5 (80 mg, 0.25 mmol) and a (186 mg, 0.25 mmol) were dissolved in dry dichloromethane (2 mL), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (143 mg, 0.38 mmol) and triethylamine (203 mg, 2.0 mmol) were added, and the reaction was carried out at 25°C for 2 hours. LCMS showed that the raw materials were completely reacted. The reaction solution was added with water (15 mL), extracted with ethyl acetate (15 mL×3), and the combined organic phases were washed with saturated brine (15 mL×3). The organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by C18 reverse phase (CH3CN:H2O=2:1) to obtain white solid compound 5-6 (80 mg, Y: 30%). LC-MS m / z(ESI):1039.7[M+H] + .
[0322] Step 7: Compound 5-6 (70 mg, 0.07 mmol) was dissolved in tetrahydrofuran (2 mL), and dioxane hydrochloride (1 mL, 4 M) was added, and the reaction was carried out at 25°C for 2 hours. LCMS showed that the reaction of the raw material was complete. The reaction solution was concentrated under reduced pressure and purified by preparative high performance liquid chromatography (column model: Xselect CSH Prep Fluoro-Phenyl, 150*19 mm, 5 um; eluent: 0.1% FA-ACN; gradient: 37-57; flow rate: 20 mL / min: running time 10 min; peak time 7 min) to obtain a white solid compound 5 (21.32 mg, Y: 34%, formate). 1H NMR (400MHz, DMSO-d6): δ10.32(s,1H),9.87(s,1H),8.31-8.18(m,2H),7.70-7.61(m,1H),7.58-7.50(m,1H),7.43-7.3 0(m,5H),7.31-7.22(m,2H),7.19(d,J=8.4Hz,1H),7.00(d,J=9.6Hz,1H),5.11(s,1H),4.96(d,J=5.6Hz,1H),3.78-3.6 7(m,1H),3.52-3.45(m,4H),3.06-2.90(m,4H),2.79-2.68(m,4H),2.63(d,J=4.8Hz,3H),2.42-2.18(m,3H),2.11(s,3H ),2.00-1.89(m,1H),1.87-1.70(m,2H),1.69-1.49(m,4H),1.46-1.20(m,4H),1.10(d,J=7.2Hz,3H),0.95-0.78(m,2H). LC-MS m / z(ESI):925.6[M+H] + .
[0323] The preparation of other compounds in this article can refer to the above examples. The information of some compounds is detailed in the table below.
[0324]
[0325]
[0326] Effect Example 1: Tumor Cell Proliferation Inhibition Experiment
[0327] The effect test experiment of the compound of the present invention selected MSTO-211H and NCI-H2052 lung cancer cells to test the inhibitory activity IC of the compound of the embodiment to inhibit cell proliferation. 50. The ATP content in the cells was quantified by the Cell Titer Glo luminescent cell viability detection kit to quantify the number of live cells. MSTO-211H, NCI-H2052 and A172 cells (ATCC) were inoculated in 96-well plates (100 μl per well) with an inoculum of 1000 cells and cultured overnight at 37°C in a 5% carbon dioxide incubator. The next day, the compound was diluted to 8 concentrations in a three-fold dilution manner and added to the 96-well plate, which was placed in a 5% carbon dioxide incubator at 37°C for three days. The culture medium was treated with the Cell Titer Glo luminescent cell viability detection kit (Promega G7570) reagent, incubated for 10 minutes, and then placed in the multi-function microplate reader Envision (Pelkin Elmer) to read the luminescent signal. DMSO was used as a control instead of the compound to calculate the inhibition rate (inhibition rate % = (1-compound signal / DMSO signal) * 100), and then the inhibitory activity IC was calculated using the standard four parameter curve fitting equation. 50 .
[0328] The compounds of the present invention have antiproliferative activity against MSTO-211H cells, NCI-H2052 cells and A172 cells. The IC 50 The data are shown in Table 1.
[0329] Table 1
[0330]
[0331] Note: ND did not perform this test.
Claims
1. A compound as shown in formula I, a solvate thereof, a pharmaceutically acceptable salt thereof or a solvate of a pharmaceutically acceptable salt thereof, A--LM I in, A is L is composed of one or more of the following structures: a single bond, -O-, C 1-10 Alkylene, C 1-10 Heteroalkylene, C 3-10 Cycloalkylene, 3-10 membered heterocycloalkylene, k Substituted C 3-10 Cycloalkylene and one or more R k Substituted 3-10 membered heterocycloalkylene; the heteroatoms of the heterocycloalkylene are selected from one, two or three of N, O and S, and the number of heteroatoms is 1, 2 or 3; the heteroatoms of the heteroalkylene are selected from one, two or three of N, O and S, and the number of heteroatoms is an integer of 1-10; Each R k Independently for C 1-6 Alkyl; M is X 1 , X 2 , X 3 and X 4 are independently a single bond, CH2, O, C(O) or NH; R 1 , R 2 , R 3 and R 4 are independently hydrogen, C 1-6 Alkyl or halogen.
2. The compound of formula I as claimed in claim 1, its solvate, its pharmaceutically acceptable salt or its pharmaceutically acceptable salt solvate, characterized in that: It meets one or more of the following conditions: (1) In L, the C 1-10 Alkylene is a straight chain alkylene; (2) In L, the C 1-10 Alkylene is C 1-6 Alkylene; (3) In L, the C 1-10 The heteroatom of the heteroalkylene group is selected from one or both of N and O, and the number of heteroatoms is 1, 2 or 3; for example, the C 1-10 The heteroatom of the heteroalkylene group is N or O; preferably, the C 1-10 The heteroatom of the heteroalkylene group is O, and the number of heteroatoms is 1, 2 or 3; or, the C 1-10 The heteroatom of the heteroalkylene group is N, and the number of heteroatoms is 1, 2 or 3; (4) In L, the C 1-10 Heteroalkylene is a straight chain heteroalkylene; (5) In L, the C 3-10 Cycloalkylene is cyclopropylene, cyclobutylene, cyclopentylene or cyclohexylene; for example, cyclobutylene or cyclohexylene, for example Another example (6) In L, the 3-10 membered heterocycloalkylene is a 3-6 membered heterocycloalkylene; (7) In L, the heteroatom of the 3-10 membered heterocycloalkylene group is N, and the number of heteroatoms is 1, 2 or 3; (8)R 1 , R 2 , R 3 and R 4 In the C 1-6 Alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl; (9)R 1 , R 2 , R 3 and R 4 wherein the halogen is independently fluorine, chlorine, bromine or iodine; (10) In M, for (11) In M, for (12) In M, for (13) In M, for (14) In L, the one or more R k Substituted C 3-10 C in cycloalkylene 3-10 Cycloalkylene is cyclopropylene, cyclobutylene, cyclopentylene or cyclohexylene, for example cyclobutylene or cyclohexylene, for example Another example (15) In L, the one or more R k The 3-10-membered heterocycloalkylene in the substituted 3-10-membered heterocycloalkylene is a 3-6-membered heterocycloalkylene; (16) In L, the one or more R k The heteroatom of the 3-10-membered heterocycloalkylene group in the substituted 3-10-membered heterocycloalkylene group is N, and the number of heteroatoms is 1, 2 or 3; and (17)R k In the C 1-6 Alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, for example methyl.
3. The compound of formula I as claimed in claim 2, its solvate, its pharmaceutically acceptable salt or its pharmaceutically acceptable salt solvate, characterized in that: It meets one or more of the following conditions: (1) In L, the C 1-10 The alkylene group is For example (2) In L, the C 1-10 The heteroalkylene group is m is 0, 1, 2, 3 or 4; for example Alternatively, the C 1-10 The heteroalkylene group is t is 1, 2, 3, 4 or 5, for example (3) In L, the C 3-10 Cycloalkylene is cyclohexylene, for example (4) In L, the 3-10 membered heterocycloalkylene group is a piperidinylene group or a piperazinylene group, for example (5)R 1 , R 2 , R 3 and R 4 In the C 1-6 The alkyl group is methyl; (6)R 1 , R 2 , R 3 and R 4 wherein the halogen is independently fluorine or chlorine; and (7) In L, the one or more R k The 3-10 membered heterocycloalkylene in the substituted 3-10 membered heterocycloalkylene is piperidinylene or piperazinylene, for example Preferably, the one or more R k The substituted 3-10 membered heterocycloalkylene is For example 4. The compound of formula I as claimed in claim 1, its solvate, its pharmaceutically acceptable salt or its pharmaceutically acceptable salt solvate, characterized in that: It meets one or more of the following conditions: (1) L is -L 1 -Y 1 -L 2 -Y 2 -L 3 -Y 3 -L 4 -L 5 -, where L 1 Connect with A, L 5 Connect with M; Y 1 , Y 2 and Y 3 are independently single bonds, C 3-10 Cycloalkylene, 3-10 membered heterocycloalkylene, one or more R k Substituted C 3-10 Cycloalkylene or one or more R k Substituted 3-10 membered heterocycloalkylene; L 1 For a single key, or C 1-10 Alkylene; L 2 for C 1-10 Alkylene or p1 and p2 are independently t is 1, 2, 3, 4 or 5; L 3 is a single bond, -O-, C 1-10 Alkylene, t is 1, 2, 3, 4 or 5, m is 0, 1, 2, 3 or 4; L 4 For a single key, or C 1-10 Alkylene; L 5 For a single key, or C 1-10 Alkylene; Preferably, L is -L 1 -Y 1 -L 2 -Y 2 -L 3 -Y 3 -L 4 -L 5 -, where L 1 Connect with A, L 5 Connect with M; Y 1 , Y 2 and Y 3 are independently single bonds, C 3-10 Cycloalkylene or 3-10 membered heterocycloalkylene; L 1 For a single key, or C 1-10 Alkylene; L 2 for or C 1-10 Alkylene; L 3 -O-, C 1-10 Alkylene or m is 0, 1, 2, 3 or 4; L 4 For a single key, or C 1-10 Alkylene; L 5 For a single key, or C 1-10 Alkylene; (2)X 1 is O or NH; (3)X 2 is C(O); (4)X 3 is O or NH; for example, X 3 is O; (5)X 4 is a single bond or CH2, such as a single bond; (6)R 1 is hydrogen; (7)R 2 is a halogen, such as fluorine; (8)R 3 C 1-6 Alkyl or halogen, such as methyl or chlorine; preferably, R 3 C 1-6 Alkyl groups, such as methyl; and (9)R 4 For hydrogen.
5. The compound of formula I as claimed in claim 4, its solvate, its pharmaceutically acceptable salt or its pharmaceutically acceptable salt solvate, characterized in that: L is any of the following options: Solution 1: L is -L 1 -Y 1 -L 2 -Y 2 -L 3 -Y 3 -L 4 -L 5 -, where L 1 Connect with A, L 5 Connect with M; L 1 is a single bond; Y 1 is a single bond or C 3-10 Cycloalkylene; L 2 for or C 1-10 Alkylene; Y 2 is a 3-10 membered heterocycloalkylene group; L 3 -O- or C 1-10 Alkylene; Y 3 is a 3-10 membered heterocycloalkylene group; L 4 For a single key or L 5 is a single bond or C 1-10 Alkylene; Solution 2: L is -L 1 -Y 1 -L 2 -Y 2 -L 3 -Y 3 -L 4 -L 5 -, where L 1 Connect with A, L 5 Connect with M; Y 1 , Y 2 and Y 3 is a single bond; L 1 for or C 1-10 Alkylene; L 2 for or C 1-10 Alkylene; L 3 C 1-10 Alkylene or m is 0, 1, 2, 3 or 4; L 4 For a single key, or C 1-10 Alkylene; L 5 For a single key, or C 1-10 Alkylene; Solution 3: L is -L 1 -Y 1 -L 2 -Y 2 -L 3 -Y 3 -L 4 -L 5 -, where L 1 Connect with A, L 5 Connect with M; L 1 is a single bond; Y 1 C 3-10 Cycloalkylene; L 2 for Y 2 and Y 3 is a single bond; L 3 for t is 1, 2, 3, 4, or 5; L 4 For a single key, or C 1-10 Alkylene; L 5 For a single key, or C 1-10 Alkylene; Solution 4: L is -L 1 -Y 1 -L 2 -Y 2 -L 3 -Y 3 -L 4 -L 5 -, where L 1 Connect with A, L 5 Connect with M; L 1 For a single key or Y 1 is a single bond; L 2 C 1-10 Alkylene or p1 and p2 are independently t is 1, 2, 3, 4 or 5; Y 2 is a single bond or C 3-10 Cycloalkylene; L 3 is a single bond, -O- or C 1-10 Alkylene; Y 3 is a 3-10 membered heterocycloalkylene group or is represented by one or more R k Substituted 3-10 membered heterocycloalkylene; L 4 For a single key, or C 1-10 Alkylene; L 5 For a single key, or C 1-10 Alkylene; Preferably, L is More preferably, L is Scheme 1 or Scheme 2, Scheme 1: L is Solution 2: L is 6. The compound of formula I according to claim 1, its solvate, its pharmaceutically acceptable salt or its pharmaceutically acceptable salt solvate, characterized in that: It meets one or more of the following conditions: (1) A is Preferably, A is (2) L is For example, L is Scheme 1 or Scheme 2. Scheme 1: L is Solution 2: L is Preferably, L is The "1" bit is connected to A, and the "2" bit is connected to M. For example, L is Scheme 1 or Scheme 2. Scheme 1: L is Among them, "1" is connected to A, and "2" is connected to M; Solution 2: L is The "1" bit is connected to A, and the "2" bit is connected to M; (3) In M, for (4) In M, for (5) In M, for Preferably, for or for (6) In M, for and (7)M is 7. The compound of formula I according to claim 1, its solvate, its pharmaceutically acceptable salt or its pharmaceutically acceptable salt solvate, characterized in that: The compound shown in formula I is any of the following: Scheme 1: L is composed of one or more of the following structures: single bond, -O-, C 1-10 Alkylene, C 1-10 Heteroalkylene, C 3-10 Cycloalkylene and 3-10 membered heterocycloalkylene; the heteroatoms of the heterocycloalkylene are selected from one, two or three of N, O and S, and the number of heteroatoms is 1, 2 or 3; the heteroatoms of the heteroalkylene are selected from one, two or three of N, O and S, and the number of heteroatoms is an integer of 1-10; Solution 2: A is L is L 1 For a single key, or C 1-10 Alkylene; L 2 for or C 1-10 Alkylene; L 3 -O-, C 1-10 Alkylene, t is 1, 2, 3, 4 or 5; m is 0, 1, 2, 3 or 4; L 4 For a single key, or C 1-10 Alkylene; L 5 For a single key, or C 1-10 Alkylene; M is X 1 is O or NH; X 3 is O or NH; R 1 and R 3 are independently hydrogen, C 1-6 Alkyl or halogen.
8. The compound of formula I as claimed in claim 1, its solvate, its pharmaceutically acceptable salt or its pharmaceutically acceptable salt solvate, characterized in that: The compound shown in formula I is any of the following compounds:
9. A compound, a solvate thereof, a pharmaceutically acceptable salt thereof, or a solvate of a pharmaceutically acceptable salt thereof, wherein the compound is any of the following compounds: R a =H, TBS, TBDPS or Me; R b=CN, CO2H, CO2Me, CO2Et, CO2tBu, CO2NH2, CO2NHMe or CO2NHEt; Preferably, for 10. A pharmaceutical composition comprising: (1) A compound of formula I as described in any one of claims 1 to 8, a solvate thereof, a pharmaceutically acceptable salt thereof, or a solvate of a pharmaceutically acceptable salt thereof; (2) Pharmaceutically acceptable excipients.
11. A use of a compound of formula I as claimed in any one of claims 1 to 8, a solvate thereof, a pharmaceutically acceptable salt thereof or a solvate of a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as claimed in claim 10 in the preparation of a medicament for preventing and / or treating cancer; Preferably, the cancer is a cancer caused by abnormal expression of YAP / TAZ; Preferably, the cancer is lung cancer, gastric adenocarcinoma, mesothelioma, solid tumor or glioblastoma; more preferably, the cancer is lung cancer, gastric adenocarcinoma, mesothelioma or solid tumor.
12. A method for preventing and / or treating cancer, comprising administering to a patient a therapeutically effective amount of a compound of formula I as described in any one of claims 1 to 8, a solvate thereof, a pharmaceutically acceptable salt thereof, or a solvate of a pharmaceutically acceptable salt thereof; Preferably, the cancer is a cancer caused by abnormal expression of YAP / TAZ; Preferably, the cancer is lung cancer, gastric adenocarcinoma, mesothelioma, solid tumor or glioblastoma; more preferably, the cancer is lung cancer, gastric adenocarcinoma, mesothelioma or solid tumor.
